



US010085799B2

(12) **United States Patent**
Smith

(10) **Patent No.:** **US 10,085,799 B2**
(45) **Date of Patent:** **Oct. 2, 2018**

(54) **OFF-WALL ELECTRODE DEVICE AND METHODS FOR NERVE MODULATION**

(71) Applicant: **Boston Scientific Scimed, Inc.**, Maple Grove, MN (US)

(72) Inventor: **Scott R. Smith**, Chaska, MN (US)

(73) Assignee: **Boston Scientific Scimed, Inc.**, Maple Grove, MN (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 1479 days.

(21) Appl. No.: **13/648,987**

(22) Filed: **Oct. 10, 2012**

(65) **Prior Publication Data**
US 2013/0090651 A1 Apr. 11, 2013

Related U.S. Application Data

(60) Provisional application No. 61/545,912, filed on Oct. 11, 2011, provisional application No. 61/605,599, filed on Mar. 1, 2012.

(51) **Int. Cl.**
A61B 18/14 (2006.01)
A61N 1/05 (2006.01)
(Continued)

(52) **U.S. Cl.**
CPC **A61B 18/1492** (2013.01); **A61N 1/0558** (2013.01); **A61B 2017/32096** (2013.01);
(Continued)

(58) **Field of Classification Search**
CPC A61B 18/1492; A61B 2018/00267; A61B 2018/00107; A61B 2018/147
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

164,184 A 6/1875 Kiddee
1,167,014 A 1/1916 O'Brien
(Continued)

FOREIGN PATENT DOCUMENTS

DE 10038737 A1 2/2002
EP 1053720 A1 11/2000
(Continued)

OTHER PUBLICATIONS


US 8,398,630, 03/2013, Demarais et al. (withdrawn)
(Continued)

Primary Examiner — Eunhwa Kim

(57) **ABSTRACT**

Systems for nerve modulation through the wall of a blood vessel are disclosed. An example system for nerve modulation may include an elongate member extending along a central elongate axis and having a proximal end and a distal end. The elongate member may have a radially expandable member disposed proximate the distal end. A tubular sheath may be cooperatively engaged with the expandable member such that the expandable member is collapsed when in the sheath and can expand when moved distally relative to and past a distal end of the sheath. The expandable member may include a plurality of electrodes and a plurality of spacer struts. Each spacer strut may be configured such that when the self-expanding member is in an expanded state the spacer strut extends out radially further than the electrodes from the central elongate axis.

20 Claims, 14 Drawing Sheets



(51)	Int. Cl.		5,304,171 A	4/1994	Gregory et al.
	<i>A61B 18/00</i>	(2006.01)	5,304,173 A	4/1994	Kittrell et al.
	<i>A61B 17/3209</i>	(2006.01)	5,306,250 A	4/1994	March et al.
(52)	U.S. Cl.		5,312,328 A	5/1994	Nita et al.
	CPC	<i>A61B 2018/00107</i> (2013.01); <i>A61B</i>	5,314,466 A	5/1994	Stern et al.
		<i>2018/00267</i> (2013.01); <i>A61B 2018/00279</i>	5,322,064 A	6/1994	Lundquist
		(2013.01)	5,324,255 A	6/1994	Passafaro et al.
			5,326,341 A	7/1994	Lew et al.
			5,326,342 A	7/1994	Pflueger et al.
			5,330,518 A	7/1994	Neilson et al.
(56)	References Cited		5,333,614 A	8/1994	Feiring
	U.S. PATENT DOCUMENTS		5,342,292 A	8/1994	Nita et al.
			5,344,395 A	9/1994	Whalen et al.
			5,364,392 A	11/1994	Warner et al.
	2,505,358 A	4/1950 Gusberg	5,365,172 A	11/1994	Hrovat et al.
	2,701,559 A	2/1955 Cooper	5,368,557 A	11/1994	Nita et al.
	3,108,593 A	10/1963 Glassman	5,368,558 A	11/1994	Nita et al.
	3,108,594 A	10/1963 Glassman	5,380,274 A	1/1995	Nita et al.
	3,540,431 A	11/1970 Mobin	5,380,319 A	1/1995	Saito et al.
	3,952,747 A	4/1976 Kimmell	5,382,228 A	1/1995	Nita et al.
	3,996,938 A	12/1976 Clark, III	5,383,874 A	1/1995	Jackson et al.
	4,046,150 A	9/1977 Schwartz et al.	5,383,917 A	1/1995	Desai et al.
	4,290,427 A	9/1981 Chin	5,397,301 A	3/1995	Pflueger et al.
	4,402,686 A	9/1983 Medel	5,397,339 A	3/1995	Desai
	4,483,341 A	11/1984 Witteles et al.	5,401,272 A	3/1995	Perkins et al.
	4,574,804 A	3/1986 Kurwa	5,403,311 A	4/1995	Abele et al.
	4,587,975 A	5/1986 Salo et al.	5,405,318 A	4/1995	Nita et al.
	4,649,936 A	3/1987 Ungar et al.	5,405,346 A	4/1995	Grundy et al.
	4,682,596 A	7/1987 Bales et al.	5,409,000 A	4/1995	Imran
	4,709,698 A	12/1987 Johnston et al.	5,417,672 A	5/1995	Nita et al.
	4,765,331 A	8/1988 Petruzzi et al.	5,419,767 A	5/1995	Eggers et al.
	4,770,653 A	9/1988 Shturman	5,427,118 A	6/1995	Nita et al.
	4,784,132 A	11/1988 Fox et al.	5,432,876 A	7/1995	Appeldorn et al.
	4,784,162 A	11/1988 Ricks et al.	5,441,498 A	8/1995	Perkins et al.
	4,785,806 A	11/1988 Deckelbaum et al.	5,447,509 A	9/1995	Mills et al.
	4,790,310 A	12/1988 Ginsburg et al.	5,451,207 A	9/1995	Yock et al.
	4,799,479 A	1/1989 Spears	5,453,091 A	9/1995	Taylor et al.
	4,823,791 A	4/1989 D'Amelio et al.	5,454,788 A	10/1995	Walker et al.
	4,830,003 A	5/1989 Wolff et al.	5,454,809 A	10/1995	Janssen
	4,849,484 A	7/1989 Heard	5,455,029 A	10/1995	Hartman et al.
	4,862,886 A	9/1989 Clarke et al.	5,456,682 A	10/1995	Edwards et al.
	4,887,605 A	12/1989 Angelsen et al.	5,457,042 A	10/1995	Hartman et al.
	4,920,979 A	5/1990 Bullara et al.	5,471,982 A	12/1995	Edwards et al.
	4,938,766 A	7/1990 Jarvik	5,474,530 A	12/1995	Passafaro et al.
	4,955,377 A	9/1990 Lennox et al.	5,478,351 A	12/1995	Meade et al.
	4,976,711 A	12/1990 Parins et al.	5,496,311 A	3/1996	Abele et al.
	5,034,010 A	7/1991 Kittrell et al.	5,496,312 A	3/1996	Klicek et al.
	5,052,402 A	10/1991 Bencini et al.	5,498,261 A	3/1996	Strul
	5,053,033 A	10/1991 Clarke et al.	5,505,201 A	4/1996	Grill et al.
	5,071,424 A	12/1991 Reger et al.	5,505,730 A	4/1996	Edwards
	5,074,871 A	12/1991 Groshong et al.	5,507,744 A	4/1996	Tay et al.
	5,098,429 A	3/1992 Sterzer et al.	5,522,873 A	6/1996	Jackman et al.
	5,098,431 A	3/1992 Rydell	5,531,520 A	7/1996	Grimson et al.
	5,109,859 A	5/1992 Jenkins	5,540,656 A	7/1996	Pflueger et al.
	5,125,928 A	6/1992 Parins et al.	5,540,679 A	7/1996	Fram et al.
	5,129,396 A	7/1992 Rosen et al.	5,540,681 A	7/1996	Strul et al.
	5,139,496 A	8/1992 Hed	5,542,917 A	8/1996	Nita et al.
	5,143,836 A	9/1992 Hartman et al.	5,545,161 A	8/1996	Imran
	5,156,610 A	10/1992 Reger et al.	5,562,100 A	10/1996	Kittrell et al.
	5,158,564 A	10/1992 Schnepp-Pesch	5,571,122 A	11/1996	Kelly et al.
	5,170,802 A	12/1992 Mehra	5,571,151 A	11/1996	Gregory
	5,178,620 A	1/1993 Eggers et al.	5,573,531 A	11/1996	Gregory et al.
	5,178,625 A	1/1993 Groshong et al.	5,573,533 A	11/1996	Strul
	5,190,540 A	3/1993 Lee	5,584,831 A	12/1996	McKay
	5,211,651 A	5/1993 Reger et al.	5,584,872 A	12/1996	Lafontaine et al.
	5,234,407 A	8/1993 Teirstein et al.	5,588,962 A	12/1996	Nicholas et al.
	5,242,441 A	9/1993 Avitall	5,599,346 A	2/1997	Edwards et al.
	5,251,634 A	10/1993 Weinberg et al.	5,601,526 A	2/1997	Chapelon et al.
	5,255,679 A	10/1993 Imran	5,609,606 A	3/1997	O'Boyle et al.
	5,263,493 A	11/1993 Avitall	5,626,576 A	5/1997	Janssen
	5,267,954 A	12/1993 Nita et al.	5,630,837 A	5/1997	Crowley
	5,277,201 A	1/1994 Stern et al.	5,637,090 A	6/1997	McGee et al.
	5,282,484 A	2/1994 Reger et al.	5,643,255 A	7/1997	Organ
	5,286,254 A	2/1994 Shapland et al.	5,643,297 A	7/1997	Nordgren et al.
	5,295,484 A	3/1994 Marcus	5,647,847 A	7/1997	Lafontaine et al.
	5,297,564 A	3/1994 Love et al.	5,649,923 A	7/1997	Gregory et al.
	5,300,068 A	4/1994 Rosar et al.	5,651,780 A	7/1997	Jackson et al.
	5,301,683 A	4/1994 Durkan	5,653,684 A	8/1997	Laptewicz et al.
	5,304,115 A	4/1994 Pflueger et al.	5,662,671 A	9/1997	Barbut et al.
	5,304,121 A	4/1994 Sahatjian			

(56)

References Cited

U.S. PATENT DOCUMENTS

5,665,062 A	9/1997	Houser	5,876,374 A	3/1999	Alba et al.
5,665,098 A	9/1997	Kelly et al.	5,876,397 A	3/1999	Edelman et al.
5,666,964 A	9/1997	Meilus	5,879,348 A	3/1999	Owens et al.
5,667,490 A	9/1997	Keith et al.	5,891,114 A	4/1999	Chien et al.
5,672,174 A	9/1997	Gough et al.	5,891,135 A	4/1999	Jackson et al.
5,676,693 A	10/1997	Lafontaine	5,891,136 A	4/1999	McGee et al.
5,678,296 A	10/1997	Fleischhacker et al.	5,891,138 A	4/1999	Tu et al.
5,681,282 A	10/1997	Eggers et al.	5,895,378 A	4/1999	Nita
RE35,656 E	11/1997	Feinberg	5,897,552 A	4/1999	Edwards et al.
5,688,266 A	11/1997	Edwards et al.	5,902,328 A	5/1999	Lafontaine et al.
5,693,015 A	12/1997	Walker et al.	5,904,651 A	5/1999	Swanson et al.
5,693,029 A	12/1997	Leonhardt et al.	5,904,667 A	5/1999	Falwell et al.
5,693,043 A	12/1997	Kittrell et al.	5,904,697 A	5/1999	Gifford et al.
5,693,082 A	12/1997	Warner et al.	5,904,709 A	5/1999	Arndt et al.
5,695,504 A	12/1997	Gifford et al.	5,906,614 A	5/1999	Stern et al.
5,697,369 A	12/1997	Long, Jr. et al.	5,906,623 A	5/1999	Peterson
5,697,909 A	12/1997	Eggers et al.	5,906,636 A	5/1999	Casscells et al.
5,702,386 A	12/1997	Stern et al.	5,916,192 A	6/1999	Nita et al.
5,702,433 A	12/1997	Taylor et al.	5,916,227 A	6/1999	Keith et al.
5,706,809 A	1/1998	Littmann et al.	5,916,239 A	6/1999	Geddes et al.
5,713,942 A	2/1998	Stern et al.	5,919,219 A	7/1999	Knowlton et al.
5,715,819 A	2/1998	Svenson et al.	5,924,424 A	7/1999	Stevens et al.
5,735,846 A	4/1998	Panescu et al.	5,925,038 A	7/1999	Panescu et al.
5,741,214 A	4/1998	Ouchi et al.	5,934,284 A	8/1999	Plaia et al.
5,741,248 A	4/1998	Stern et al.	5,935,063 A	8/1999	Nguyen
5,741,249 A	4/1998	Moss et al.	5,938,670 A	8/1999	Keith et al.
5,743,903 A	4/1998	Stern et al.	5,947,977 A	9/1999	Slepian et al.
5,748,347 A	5/1998	Erickson	5,948,011 A	9/1999	Knowlton et al.
5,749,914 A	5/1998	Janssen	5,951,494 A	9/1999	Wang et al.
5,755,682 A	5/1998	Knudson et al.	5,951,539 A	9/1999	Nita et al.
5,755,715 A	5/1998	Stern et al.	5,954,717 A	9/1999	Behl et al.
5,755,753 A	5/1998	Knowlton et al.	5,957,882 A	9/1999	Nita et al.
5,769,847 A	6/1998	Panescu et al.	5,957,941 A	9/1999	Ream et al.
5,769,880 A	6/1998	Truckai et al.	5,957,969 A	9/1999	Warner et al.
5,775,338 A	7/1998	Hastings	5,961,513 A	10/1999	Swanson et al.
5,776,174 A	7/1998	Van Tassel	5,964,757 A	10/1999	Ponzi et al.
5,779,698 A	7/1998	Clayman et al.	5,967,976 A	10/1999	Larsen et al.
5,782,760 A	7/1998	Schaer	5,967,978 A	10/1999	Littmann et al.
5,785,702 A	7/1998	Murphy et al.	5,967,984 A	10/1999	Chu et al.
5,797,849 A	8/1998	Vesely et al.	5,971,975 A	10/1999	Mills et al.
5,797,903 A	8/1998	Swanson et al.	5,972,026 A	10/1999	Laufer et al.
5,800,484 A	9/1998	Gough et al.	5,980,563 A	11/1999	Tu et al.
5,800,494 A	9/1998	Campbell et al.	5,989,208 A	11/1999	Nita et al.
5,810,802 A	9/1998	Panescu et al.	5,989,284 A	11/1999	Laufer
5,810,803 A	9/1998	Moss et al.	5,993,462 A	11/1999	Pomeranz et al.
5,810,810 A	9/1998	Tay et al.	5,997,497 A	12/1999	Nita et al.
5,817,092 A	10/1998	Behl	5,999,678 A	12/1999	Murphy et al.
5,817,113 A	10/1998	Gifford et al.	6,004,269 A	12/1999	Crowley et al.
5,817,144 A	10/1998	Gregory et al.	6,004,316 A	12/1999	Laufer et al.
5,823,956 A	10/1998	Roth et al.	6,007,514 A	12/1999	Nita
5,827,203 A	10/1998	Nita et al.	6,010,522 A	1/2000	Barbut et al.
5,827,268 A	10/1998	Laufer	6,013,033 A	1/2000	Berger et al.
5,829,447 A	11/1998	Stevens et al.	6,014,590 A	1/2000	Whayne et al.
5,830,213 A	11/1998	Panescu et al.	6,022,309 A	2/2000	Celliers et al.
5,830,222 A	11/1998	Makower	6,024,740 A	2/2000	Lesh
5,832,228 A	11/1998	Holden et al.	6,030,611 A	2/2000	Gorecki et al.
5,833,593 A	11/1998	Liprie	6,032,675 A	3/2000	Rubinsky et al.
5,836,874 A	11/1998	Swanson et al.	6,033,397 A	3/2000	Laufer et al.
5,840,076 A	11/1998	Swanson et al.	6,033,398 A	3/2000	Farley et al.
5,843,016 A	12/1998	Lugnani et al.	6,036,687 A	3/2000	Laufer et al.
5,846,238 A	12/1998	Jackson et al.	6,036,689 A	3/2000	Tu et al.
5,846,239 A	12/1998	Swanson et al.	6,041,260 A	3/2000	Stern et al.
5,846,245 A	12/1998	McCarthy et al.	6,050,994 A	4/2000	Sherman et al.
5,848,969 A	12/1998	Panescu et al.	6,056,744 A	5/2000	Edwards
5,853,411 A	12/1998	Whayne et al.	6,056,746 A	5/2000	Goble et al.
5,855,614 A	1/1999	Stevens et al.	6,063,085 A	5/2000	Tay et al.
5,860,974 A	1/1999	Abele	6,066,096 A	5/2000	Smith et al.
5,865,801 A	2/1999	Houser	6,066,139 A	5/2000	Ryan et al.
5,868,735 A	2/1999	Lafontaine et al.	6,068,638 A	5/2000	Makower
5,868,736 A	2/1999	Swanson et al.	6,068,653 A	5/2000	Lafontaine
5,871,483 A	2/1999	Jackson et al.	6,071,277 A	6/2000	Farley et al.
5,871,524 A	2/1999	Knowlton et al.	6,071,278 A	6/2000	Panescu et al.
4,788,975 B1	3/1999	Shturman et al.	6,078,839 A	6/2000	Carson
5,875,782 A	3/1999	Ferrari et al.	6,079,414 A	6/2000	Roth
5,876,369 A	3/1999	Houser	6,080,171 A	6/2000	Keith et al.
			6,081,749 A	6/2000	Ingle et al.
			6,086,581 A	7/2000	Reynolds et al.
			6,093,166 A	7/2000	Knudson et al.
			6,096,021 A	8/2000	Helm et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

6,099,526 A	8/2000	Whayne et al.	6,298,256 B1	10/2001	Meyer
6,102,908 A	8/2000	Tu et al.	6,299,379 B1	10/2001	Lewis
6,106,477 A	8/2000	Miesel et al.	6,299,623 B1	10/2001	Wulfman
6,110,187 A	8/2000	Donlon et al.	6,309,379 B1	10/2001	Willard et al.
6,114,311 A	9/2000	Parmacek et al.	6,309,399 B1	10/2001	Barbut et al.
6,117,101 A	9/2000	Diederich et al.	6,311,090 B1	10/2001	Knowlton
6,117,128 A	9/2000	Gregory	6,317,615 B1	11/2001	KenKnight et al.
6,120,476 A	9/2000	Fung et al.	6,319,242 B1	11/2001	Patterson et al.
6,120,516 A	9/2000	Selmon et al.	6,319,251 B1	11/2001	Tu et al.
6,121,775 A	9/2000	Pearlman	6,322,559 B1	11/2001	Daulton et al.
6,123,679 A	9/2000	Lafaut et al.	6,325,797 B1	12/2001	Stewart et al.
6,123,682 A	9/2000	Knudson et al.	6,325,799 B1	12/2001	Goble
6,123,702 A	9/2000	Swanson et al.	6,328,699 B1	12/2001	Eigler et al.
6,123,703 A	9/2000	Tu et al.	6,346,074 B1	2/2002	Roth
6,123,718 A	9/2000	Tu et al.	6,346,104 B2	2/2002	Daly et al.
6,129,725 A	10/2000	Tu et al.	6,350,248 B1	2/2002	Knudson et al.
6,135,997 A	10/2000	Laufer et al.	6,350,276 B1	2/2002	Knowlton
6,142,991 A	11/2000	Schatzberger et al.	6,353,751 B1	3/2002	Swanson et al.
6,142,993 A	11/2000	Whayne et al.	6,355,029 B1	3/2002	Joye et al.
6,149,647 A	11/2000	Tu et al.	6,357,447 B1	3/2002	Swanson et al.
6,152,899 A	11/2000	Farley et al.	6,361,519 B1	3/2002	Knudson et al.
6,152,912 A	11/2000	Jansen et al.	6,364,840 B1	4/2002	Crowley
6,156,046 A	12/2000	Passafaro et al.	6,371,965 B2	4/2002	Gifford, III et al.
6,158,250 A	12/2000	Tibbals et al.	6,375,668 B1	4/2002	Gifford et al.
6,159,187 A	12/2000	Park et al.	6,377,854 B1	4/2002	Knowlton
6,159,225 A	12/2000	Makower	6,377,855 B1	4/2002	Knowlton
6,161,048 A	12/2000	Sluijter et al.	6,379,352 B1	4/2002	Reynolds et al.
6,162,184 A	12/2000	Swanson et al.	6,379,373 B1	4/2002	Sawhney et al.
6,165,163 A	12/2000	Chien et al.	6,381,497 B1	4/2002	Knowlton
6,165,172 A	12/2000	Farley et al.	6,381,498 B1	4/2002	Knowlton
6,165,187 A	12/2000	Reger et al.	6,383,151 B1	5/2002	Diederich et al.
6,168,594 B1	1/2001	Lafontaine et al.	6,387,105 B1	5/2002	Gifford, III et al.
6,171,321 B1	1/2001	Gifford, III et al.	6,387,380 B1	5/2002	Knowlton
6,179,832 B1	1/2001	Jones et al.	6,389,311 B1	5/2002	Whayne et al.
6,179,835 B1	1/2001	Panescu et al.	6,389,314 B2	5/2002	Feiring
6,179,859 B1	1/2001	Bates et al.	6,391,024 B1	5/2002	Sun et al.
6,183,468 B1	2/2001	Swanson et al.	6,394,096 B1	5/2002	Constantz
6,183,486 B1	2/2001	Snow et al.	6,394,956 B1	5/2002	Chandrasekaran et al.
6,190,379 B1	2/2001	Heuser et al.	6,398,780 B1	6/2002	Farley et al.
6,191,862 B1	2/2001	Swanson et al.	6,398,782 B1	6/2002	Pecor et al.
6,197,021 B1	3/2001	Panescu et al.	6,398,792 B1	6/2002	O'Connor
6,200,266 B1	3/2001	Shokrollahi et al.	6,401,720 B1	6/2002	Stevens et al.
6,203,537 B1	3/2001	Adrian	6,402,719 B1	6/2002	Ponzi et al.
6,203,561 B1	3/2001	Ramee et al.	6,405,090 B1	6/2002	Knowlton
6,210,406 B1	4/2001	Webster	6,409,723 B1	6/2002	Edwards
6,211,247 B1	4/2001	Goodman	6,413,255 B1 *	7/2002	Stern A61B 18/14 606/41
6,217,576 B1	4/2001	Tu et al.	6,421,559 B1	7/2002	Pearlman
6,219,577 B1	4/2001	Brown, III et al.	6,423,057 B1	7/2002	He et al.
6,228,076 B1	5/2001	Winston et al.	6,425,867 B1	7/2002	Vaezy et al.
6,228,109 B1	5/2001	Tu et al.	6,425,912 B1	7/2002	Knowlton
6,231,516 B1	5/2001	Keilman et al.	6,427,118 B1	7/2002	Suzuki
6,231,587 B1	5/2001	Makower	6,428,534 B1	8/2002	Joye et al.
6,235,044 B1	5/2001	Root et al.	6,428,536 B2	8/2002	Panescu et al.
6,236,883 B1	5/2001	Ciaccio et al.	6,430,446 B1	8/2002	Knowlton
6,237,605 B1	5/2001	Vaska et al.	6,432,102 B2	8/2002	Joye et al.
6,238,389 B1	5/2001	Paddock et al.	6,436,056 B1	8/2002	Wang et al.
6,238,392 B1	5/2001	Long	6,438,424 B1	8/2002	Knowlton
6,241,666 B1	6/2001	Pomeranz et al.	6,440,125 B1	8/2002	Rentrop
6,241,753 B1	6/2001	Knowlton	6,442,413 B1	8/2002	Silver
6,245,020 B1	6/2001	Moore et al.	6,443,965 B1	9/2002	Gifford, III et al.
6,245,045 B1	6/2001	Stratienko	6,445,939 B1	9/2002	Swanson et al.
6,248,126 B1	6/2001	Lesser et al.	6,447,505 B2	9/2002	McGovern et al.
6,251,128 B1	6/2001	Knopp et al.	6,447,509 B1	9/2002	Bonnet et al.
6,258,087 B1	7/2001	Edwards et al.	6,451,034 B1	9/2002	Gifford, III et al.
6,273,886 B1	8/2001	Edwards et al.	6,451,044 B1	9/2002	Naghavi et al.
6,280,466 B1	8/2001	Kugler et al.	6,453,202 B1	9/2002	Knowlton
6,283,935 B1	9/2001	Laufer et al.	6,454,737 B1	9/2002	Nita et al.
6,283,959 B1	9/2001	Lalonde et al.	6,454,757 B1	9/2002	Nita et al.
6,284,743 B1	9/2001	Parmacek et al.	6,454,775 B1	9/2002	Demarais et al.
6,287,323 B1	9/2001	Hammerslag	6,458,098 B1	10/2002	Kanesaka
6,290,696 B1	9/2001	Lafontaine	6,461,378 B1	10/2002	Knowlton
6,292,695 B1	9/2001	Webster, Jr. et al.	6,468,276 B1	10/2002	McKay
6,293,942 B1	9/2001	Goble et al.	6,468,297 B1	10/2002	Williams et al.
6,293,943 B1	9/2001	Panescu et al.	6,470,216 B1	10/2002	Knowlton
6,296,619 B1	10/2001	Briskens et al.	6,470,219 B1	10/2002	Edwards et al.
			6,471,696 B1	10/2002	Berube et al.
			6,475,213 B1	11/2002	Whayne et al.
			6,475,215 B1	11/2002	Tanrisever

(56)

References Cited

U.S. PATENT DOCUMENTS

6,475,238 B1	11/2002	Fedida et al.	6,669,655 B1	12/2003	Acker et al.
6,477,426 B1	11/2002	Fenn et al.	6,669,692 B1	12/2003	Nelson et al.
6,480,745 B2	11/2002	Nelson et al.	6,673,040 B1	1/2004	Samson et al.
6,481,704 B1	11/2002	Koster et al.	6,673,064 B1	1/2004	Rentrop
6,482,202 B1	11/2002	Goble et al.	6,673,066 B2	1/2004	Werneth
6,484,052 B1	11/2002	Visuri et al.	6,673,090 B2	1/2004	Root et al.
6,485,489 B2	11/2002	Teirstein et al.	6,673,101 B1	1/2004	Fitzgerald et al.
6,488,679 B1	12/2002	Swanson et al.	6,673,290 B1	1/2004	Whayne et al.
6,489,307 B1	12/2002	Phillips et al.	6,676,678 B2	1/2004	Gifford, III et al.
6,491,705 B2	12/2002	Gifford, III et al.	6,679,268 B2	1/2004	Stevens et al.
6,494,891 B1	12/2002	Cornish et al.	6,681,773 B2	1/2004	Murphy et al.
6,497,711 B1	12/2002	Plaia et al.	6,682,541 B1	1/2004	Gifford, III et al.
6,500,172 B1	12/2002	Panescu et al.	6,684,098 B2	1/2004	Oshio et al.
6,500,174 B1	12/2002	Maguire et al.	6,685,732 B2	2/2004	Kramer
6,508,765 B2	1/2003	Suorsa et al.	6,685,733 B1	2/2004	Dae et al.
6,508,804 B2	1/2003	Sarge et al.	6,689,086 B1	2/2004	Nita et al.
6,508,815 B1	1/2003	Strul et al.	6,689,148 B2	2/2004	Sawhney et al.
6,511,478 B1	1/2003	Burnside et al.	6,690,181 B1	2/2004	Dowdeswell et al.
6,511,496 B1	1/2003	Huter et al.	6,692,490 B1	2/2004	Edwards
6,511,500 B1	1/2003	Rahme	6,695,830 B2	2/2004	Vigil et al.
6,514,236 B1	2/2003	Stratienko	6,695,857 B2	2/2004	Gifford, III et al.
6,514,245 B1	2/2003	Williams et al.	6,699,241 B2	3/2004	Rappaport et al.
6,514,248 B1	2/2003	Eggers et al.	6,699,257 B2	3/2004	Gifford, III et al.
6,517,534 B1	2/2003	McGovern et al.	6,702,748 B1	3/2004	Nita et al.
6,517,572 B2	2/2003	Kugler et al.	6,702,811 B2	3/2004	Stewart et al.
6,522,913 B2	2/2003	Swanson et al.	6,706,010 B1	3/2004	Miki et al.
6,522,926 B1	2/2003	Kieval et al.	6,706,011 B1	3/2004	Murphy-Chutorian et al.
6,524,299 B1	2/2003	Tran et al.	6,706,037 B2	3/2004	Zvuloni et al.
6,527,765 B2	3/2003	Kelman et al.	6,709,431 B2	3/2004	Lafontaine
6,527,769 B2	3/2003	Langberg et al.	6,711,429 B1	3/2004	Gilboa et al.
6,540,761 B2	4/2003	Houser	6,712,815 B2	3/2004	Sampson et al.
6,542,781 B1	4/2003	Koblisch et al.	6,714,822 B2	3/2004	King et al.
6,544,780 B1	4/2003	Wang	6,716,184 B2	4/2004	Vaezy et al.
6,546,272 B1	4/2003	MacKinnon et al.	6,720,350 B2	4/2004	Kunz et al.
6,547,788 B1	4/2003	Maguire et al.	6,723,043 B2	4/2004	Kleeman et al.
6,549,800 B1	4/2003	Atalar et al.	6,723,064 B2	4/2004	Babaev
6,552,796 B2	4/2003	Magnin et al.	6,736,811 B2	5/2004	Panescu et al.
6,554,780 B1	4/2003	Sampson et al.	6,743,184 B2	6/2004	Sampson et al.
6,558,381 B2	5/2003	Ingle et al.	6,746,401 B2	6/2004	Panescu
6,558,382 B2	5/2003	Jahns et al.	6,746,464 B1	6/2004	Makower
6,564,096 B2	5/2003	Mest	6,746,474 B2	6/2004	Saadat
6,565,582 B2	5/2003	Gifford, III et al.	6,748,953 B2	6/2004	Sherry et al.
6,569,109 B2	5/2003	Sakurai et al.	6,749,607 B2	6/2004	Edwards et al.
6,569,177 B1	5/2003	Dillard et al.	6,752,805 B2	6/2004	Maguire et al.
6,570,659 B2	5/2003	Schmitt	6,760,616 B2	7/2004	Hoey et al.
6,572,551 B1	6/2003	Smith et al.	6,763,261 B2	7/2004	Casscells, III et al.
6,572,612 B2	6/2003	Stewart et al.	6,764,501 B2	7/2004	Ganz
6,577,902 B1	6/2003	Laufer et al.	6,769,433 B2	8/2004	Zikorus et al.
6,579,308 B1	6/2003	Jansen et al.	6,770,070 B1	8/2004	Balbierz
6,579,311 B1	6/2003	Makower	6,771,996 B2	8/2004	Bowe et al.
6,582,423 B1	6/2003	Thapliyal et al.	6,773,433 B2	8/2004	Stewart et al.
6,589,238 B2	7/2003	Edwards et al.	6,786,900 B2	9/2004	Joye et al.
6,592,526 B1	7/2003	Lenker	6,786,901 B2	9/2004	Joye et al.
6,592,567 B1	7/2003	Levin et al.	6,786,904 B2	9/2004	Döscher et al.
6,595,959 B1	7/2003	Stratienko	6,788,977 B2	9/2004	Fenn et al.
6,600,956 B2	7/2003	Maschino et al.	6,790,206 B2	9/2004	Panescu
6,602,242 B1	8/2003	Fung	6,790,222 B2	9/2004	Kugler et al.
6,602,246 B1	8/2003	Joye et al.	6,796,981 B2	9/2004	Wham et al.
6,605,084 B2	8/2003	Acker et al.	6,797,933 B1	9/2004	Mendis et al.
6,623,452 B2	9/2003	Chien et al.	6,797,960 B1	9/2004	Spartiotis et al.
6,623,453 B1	9/2003	Guibert et al.	6,800,075 B2	10/2004	Mische et al.
6,632,193 B1	10/2003	Davison et al.	6,802,857 B1	10/2004	Walsh et al.
6,632,196 B1	10/2003	Houser	6,807,444 B2	10/2004	Tu et al.
6,645,223 B2	11/2003	Boyle et al.	6,811,550 B2	11/2004	Holland et al.
6,648,854 B1	11/2003	Patterson et al.	6,813,520 B2	11/2004	Truckai et al.
6,648,878 B2	11/2003	Lafontaine	6,814,730 B2	11/2004	Li
6,648,879 B2	11/2003	Joye et al.	6,814,733 B2	11/2004	Schwartz et al.
6,651,672 B2	11/2003	Roth	6,823,205 B1	11/2004	Jara
6,652,513 B2	11/2003	Panescu et al.	6,824,516 B2	11/2004	Batten et al.
6,652,515 B1	11/2003	Maguire et al.	6,827,726 B2	12/2004	Parodi
6,656,136 B1	12/2003	Weng et al.	6,827,926 B2	12/2004	Robinson et al.
6,658,279 B2	12/2003	Swanson et al.	6,829,497 B2	12/2004	Mogul
6,659,981 B2	12/2003	Stewart et al.	6,830,568 B1	12/2004	Kesten et al.
6,666,858 B2	12/2003	Lafontaine	6,837,886 B2	1/2005	Collins et al.
6,666,863 B2	12/2003	Wentzel et al.	6,837,888 B2	1/2005	Ciarrocca et al.
			6,845,267 B2	1/2005	Harrison
			6,847,848 B2	1/2005	Sterzer
			6,849,073 B2	2/2005	Hoey et al.
			6,849,075 B2	2/2005	Bertolero et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

6,853,425 B2	2/2005	Kim et al.	7,087,026 B2	8/2006	Callister et al.
6,855,123 B2	2/2005	Nita	7,087,051 B2	8/2006	Bourne et al.
6,855,143 B2	2/2005	Davison	7,087,052 B2	8/2006	Sampson et al.
6,869,431 B2	3/2005	Maguire et al.	7,087,053 B2	8/2006	Vanney
6,872,183 B2	3/2005	Sampson et al.	7,089,065 B2	8/2006	Westlund et al.
6,884,260 B2	4/2005	Kugler et al.	7,097,641 B1	8/2006	Arless et al.
6,889,694 B2	5/2005	Hooven	7,100,614 B2	9/2006	Stevens et al.
6,893,436 B2	5/2005	Woodard et al.	7,101,368 B2	9/2006	Lafontaine
6,895,077 B2	5/2005	Karellas et al.	7,104,983 B2	9/2006	Grasso, III et al.
6,895,265 B2	5/2005	Silver	7,104,987 B2	9/2006	Biggs et al.
6,898,454 B2	5/2005	Atalar et al.	7,108,715 B2	9/2006	Lawrence-Brown et al.
6,899,711 B2	5/2005	Stewart et al.	7,112,196 B2	9/2006	Brosch et al.
6,899,718 B2	5/2005	Gifford, III et al.	7,112,198 B2	9/2006	Satake
6,905,494 B2	6/2005	Yon et al.	7,112,211 B2	9/2006	Gifford, III et al.
6,908,462 B2	6/2005	Joye et al.	7,122,019 B1	10/2006	Kesten et al.
6,909,009 B2	6/2005	Koridze	7,122,033 B2	10/2006	Wood
6,911,026 B1	6/2005	Hall et al.	7,134,438 B2	11/2006	Makower et al.
6,915,806 B2	7/2005	Pacek et al.	7,137,963 B2	11/2006	Nita et al.
6,923,805 B1	8/2005	LaFontaine et al.	7,137,980 B2	11/2006	Buysse et al.
6,926,246 B2	8/2005	Ginggen	7,153,315 B2	12/2006	Miller
6,926,713 B2	8/2005	Rioux et al.	7,155,271 B2	12/2006	Halperin et al.
6,926,716 B2	8/2005	Baker et al.	7,157,491 B2	1/2007	Mewshaw et al.
6,929,009 B2	8/2005	Makower et al.	7,157,492 B2	1/2007	Mewshaw et al.
6,929,632 B2	8/2005	Nita et al.	7,158,832 B2	1/2007	Kieval et al.
6,929,639 B2	8/2005	Lafontaine	7,160,296 B2	1/2007	Pearson et al.
6,932,776 B2	8/2005	Carr	7,162,303 B2	1/2007	Levin et al.
6,936,047 B2	8/2005	Nasab et al.	7,165,551 B2	1/2007	Edwards et al.
6,942,620 B2	9/2005	Nita et al.	7,169,144 B2	1/2007	Hoey et al.
6,942,657 B2	9/2005	Sinofsky et al.	7,172,589 B2	2/2007	Lafontaine
6,942,677 B2	9/2005	Nita et al.	7,172,610 B2	2/2007	Heitzmann et al.
6,942,692 B2	9/2005	Landau et al.	7,181,261 B2	2/2007	Silver et al.
6,949,097 B2	9/2005	Stewart et al.	7,184,811 B2	2/2007	Phan et al.
6,949,121 B1	9/2005	Laguna	7,184,827 B1	2/2007	Edwards
6,952,615 B2	10/2005	Satake	7,189,227 B2	3/2007	Lafontaine
6,953,425 B2	10/2005	Brister	7,192,427 B2	3/2007	Chapelon et al.
6,955,174 B2	10/2005	Joye et al.	7,192,586 B2	3/2007	Bander
6,955,175 B2	10/2005	Stevens et al.	7,197,354 B2	3/2007	Sobe
6,959,711 B2	11/2005	Murphy et al.	7,198,632 B2	4/2007	Lim et al.
6,960,207 B2	11/2005	Vanney et al.	7,200,445 B1	4/2007	Dalbec et al.
6,962,584 B1	11/2005	Stone et al.	7,201,749 B2	4/2007	Govari et al.
6,964,660 B2	11/2005	Maguire et al.	7,203,537 B2	4/2007	Mower
6,966,908 B2	11/2005	Maguire et al.	7,214,234 B2	5/2007	Rapacki et al.
6,972,015 B2	12/2005	Joye et al.	7,220,233 B2	5/2007	Nita et al.
6,972,024 B1	12/2005	Kilpatrick et al.	7,220,239 B2	5/2007	Wilson et al.
6,974,456 B2	12/2005	Edwards et al.	7,220,257 B1	5/2007	Lafontaine
6,978,174 B2	12/2005	Gelfand et al.	7,220,270 B2	5/2007	Sawhney et al.
6,979,329 B2	12/2005	Burnside et al.	7,232,458 B2	6/2007	Saadat
6,979,420 B2	12/2005	Weber	7,232,459 B2	6/2007	Greenberg et al.
6,984,238 B2	1/2006	Gifford, III et al.	7,238,184 B2	7/2007	Megerman et al.
6,985,774 B2	1/2006	Kieval et al.	7,241,273 B2	7/2007	Maguire et al.
6,986,739 B2	1/2006	Warren et al.	7,241,736 B2	7/2007	Hunter et al.
6,989,009 B2	1/2006	Lafontaine	7,247,141 B2	7/2007	Makin et al.
6,989,010 B2	1/2006	Francischelli et al.	7,250,041 B2	7/2007	Chiu et al.
6,991,617 B2	1/2006	Hektner et al.	7,250,440 B2	7/2007	Mewshaw et al.
7,001,378 B2	2/2006	Yon et al.	7,252,664 B2	8/2007	Nasab et al.
7,006,858 B2	2/2006	Silver et al.	7,252,679 B2	8/2007	Fischell et al.
7,022,105 B1	4/2006	Edwards	7,264,619 B2	9/2007	Venturelli
7,022,120 B2	4/2006	Lafontaine	7,279,600 B2	10/2007	Mewshaw et al.
7,025,767 B2	4/2006	Schaefer et al.	7,280,863 B2	10/2007	Shachar
7,033,322 B2	4/2006	Silver	7,282,213 B2	10/2007	Schroeder et al.
7,033,372 B1	4/2006	Cahalan	7,285,119 B2	10/2007	Stewart et al.
7,041,098 B2	5/2006	Farley et al.	7,285,120 B2	10/2007	Im et al.
7,050,848 B2	5/2006	Hoey et al.	7,288,089 B2	10/2007	Yon et al.
7,063,670 B2	6/2006	Sampson et al.	7,288,096 B2	10/2007	Chin
7,063,679 B2	6/2006	Maguire et al.	7,291,146 B2	11/2007	Steinke et al.
7,063,719 B2	6/2006	Jansen et al.	7,293,562 B2	11/2007	Malecki et al.
7,066,895 B2	6/2006	Podany	7,294,125 B2	11/2007	Phalen et al.
7,066,900 B2	6/2006	Botto et al.	7,294,126 B2	11/2007	Sampson et al.
7,066,904 B2	6/2006	Rosenthal et al.	7,294,127 B2	11/2007	Leung et al.
7,072,720 B2	7/2006	Puskas	7,297,131 B2	11/2007	Nita
7,074,217 B2	7/2006	Strul et al.	7,297,475 B2	11/2007	Koiwai et al.
7,081,112 B2	7/2006	Joye et al.	7,300,433 B2	11/2007	Lane et al.
7,081,114 B2	7/2006	Rashidi	7,301,108 B2	11/2007	Egitto et al.
7,083,614 B2	8/2006	Fjield et al.	7,310,150 B2	12/2007	Guillermo et al.
7,084,276 B2	8/2006	Vu et al.	7,313,430 B2	12/2007	Urquhart et al.
			7,314,483 B2	1/2008	Landau et al.
			7,317,077 B2	1/2008	Averback et al.
			7,323,006 B2	1/2008	Andreas et al.
			7,326,206 B2	2/2008	Paul et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

7,326,226 B2	2/2008	Root et al.	7,598,228 B2	10/2009	Hattori et al.
7,326,235 B2	2/2008	Edwards	7,599,730 B2	10/2009	Hunter et al.
7,326,237 B2	2/2008	DePalma et al.	7,603,166 B2	10/2009	Casscells, III et al.
7,329,236 B2	2/2008	Kesten et al.	7,604,608 B2	10/2009	Nita et al.
7,335,180 B2	2/2008	Nita et al.	7,604,633 B2	10/2009	Truckai et al.
7,335,192 B2	2/2008	Keren et al.	7,615,015 B2	11/2009	Coleman
7,338,467 B2	3/2008	Lutter	7,615,072 B2	11/2009	Rust et al.
7,341,570 B2	3/2008	Keren et al.	7,617,005 B2	11/2009	Demarais et al.
7,343,195 B2	3/2008	Strommer et al.	7,620,451 B2	11/2009	Demarais et al.
7,347,857 B2	3/2008	Anderson et al.	7,621,902 B2	11/2009	Nita et al.
7,348,003 B2	3/2008	Salcedo et al.	7,621,929 B2	11/2009	Nita et al.
7,352,593 B2	4/2008	Zeng et al.	7,626,015 B2	12/2009	Feinstein et al.
7,354,927 B2	4/2008	Vu	7,626,235 B2	12/2009	Kinoshita
7,359,732 B2	4/2008	Kim et al.	7,632,268 B2	12/2009	Edwards et al.
7,361,341 B2	4/2008	Salcedo et al.	7,632,845 B2	12/2009	Vu et al.
7,364,566 B2	4/2008	Elkins et al.	7,635,383 B2	12/2009	Gumm
7,367,970 B2	5/2008	Govari et al.	7,640,046 B2	12/2009	Pastore et al.
7,367,975 B2	5/2008	Malecki et al.	7,641,633 B2	1/2010	Laufer et al.
7,371,231 B2	5/2008	Rioux et al.	7,641,679 B2	1/2010	Joye et al.
7,387,126 B2	6/2008	Cox et al.	7,646,544 B2	1/2010	Batchko et al.
7,393,338 B2	7/2008	Nita	7,647,115 B2	1/2010	Levin et al.
7,396,355 B2	7/2008	Goldman et al.	7,653,438 B2	1/2010	Deem et al.
7,402,151 B2	7/2008	Rosenman et al.	7,655,006 B2	2/2010	Sauvageau et al.
7,402,312 B2	7/2008	Rosen et al.	7,662,114 B2	2/2010	Seip et al.
7,404,824 B1	7/2008	Webler et al.	7,664,548 B2	2/2010	Amurthur et al.
7,406,970 B2	8/2008	Zikorus et al.	7,670,279 B2	3/2010	Gertner
7,407,502 B2	8/2008	Strul et al.	7,670,335 B2	3/2010	Keidar
7,407,506 B2	8/2008	Makower	7,671,084 B2	3/2010	Mewshaw et al.
7,407,671 B2	8/2008	McBride et al.	7,678,104 B2	3/2010	Keidar
7,408,021 B2	8/2008	Averback et al.	7,678,106 B2	3/2010	Lee
7,410,486 B2	8/2008	Fuimaono et al.	7,678,108 B2	3/2010	Christian et al.
7,413,556 B2	8/2008	Zhang et al.	7,691,080 B2	4/2010	Seward et al.
7,425,212 B1	9/2008	Danek et al.	7,699,809 B2	4/2010	Urmey
7,426,409 B2	9/2008	Casscells, III et al.	7,706,882 B2	4/2010	Francischelli et al.
7,435,248 B2	10/2008	Taimisto et al.	7,715,912 B2	5/2010	Rezai et al.
7,447,453 B2	11/2008	Kim et al.	7,717,853 B2	5/2010	Nita
7,449,018 B2	11/2008	Kramer	7,717,909 B2	5/2010	Strul et al.
7,452,538 B2	11/2008	Ni et al.	7,717,948 B2	5/2010	Demarais et al.
7,473,890 B2	1/2009	Grier et al.	7,722,539 B2	5/2010	Carter et al.
7,476,384 B2	1/2009	Ni et al.	7,725,157 B2	5/2010	Dumoulin et al.
7,479,157 B2	1/2009	Weber et al.	7,727,178 B2	6/2010	Wilson et al.
7,481,803 B2	1/2009	Kesten et al.	7,736,317 B2	6/2010	Stephens et al.
7,485,104 B2	2/2009	Kieval	7,736,360 B2	6/2010	Mody et al.
7,486,805 B2	2/2009	Krattiger	7,736,362 B2	6/2010	Eberl et al.
7,487,780 B2	2/2009	Hooven	7,738,952 B2	6/2010	Yun et al.
7,493,154 B2	2/2009	Bonner et al.	7,740,629 B2	6/2010	Anderson et al.
7,494,485 B2	2/2009	Beck et al.	7,741,299 B2	6/2010	Feinstein et al.
7,494,486 B2	2/2009	Mische et al.	7,742,795 B2	6/2010	Stone et al.
7,494,488 B2	2/2009	Weber	7,744,594 B2	6/2010	Yamazaki et al.
7,494,661 B2	2/2009	Sanders	7,753,907 B2	7/2010	DiMatteo et al.
7,495,439 B2	2/2009	Wiggins	7,756,583 B2	7/2010	Demarais et al.
7,497,858 B2	3/2009	Chapelon et al.	7,758,510 B2	7/2010	Nita et al.
7,499,745 B2	3/2009	Littrup et al.	7,758,520 B2	7/2010	Griffin et al.
7,500,985 B2	3/2009	Saadat	7,759,315 B2	7/2010	Cuzzocrea et al.
7,505,812 B1	3/2009	Eggers et al.	7,766,833 B2	8/2010	Lee et al.
7,505,816 B2	3/2009	Schmeling et al.	7,766,878 B2	8/2010	Tremaglio, Jr. et al.
7,507,233 B2	3/2009	Littrup et al.	7,766,892 B2	8/2010	Keren et al.
7,507,235 B2	3/2009	Keogh et al.	7,767,844 B2	8/2010	Lee et al.
7,511,494 B2	3/2009	Wedeen	7,769,427 B2	8/2010	Shachar
7,512,445 B2	3/2009	Truckai et al.	7,771,372 B2	8/2010	Wilson
7,527,643 B2	5/2009	Case et al.	7,771,421 B2	8/2010	Stewart et al.
7,529,589 B2	5/2009	Williams et al.	7,776,967 B2	8/2010	Perry et al.
7,540,852 B2	6/2009	Nita et al.	7,777,486 B2	8/2010	Hargreaves et al.
7,540,870 B2	6/2009	Babaev	7,780,660 B2	8/2010	Bourne et al.
RE40,863 E	7/2009	Tay et al.	7,789,876 B2	9/2010	Zikorus et al.
7,556,624 B2	7/2009	Laufer et al.	7,792,568 B2	9/2010	Zhong et al.
7,558,625 B2	7/2009	Levin et al.	7,799,021 B2	9/2010	Leung et al.
7,563,247 B2	7/2009	Maguire et al.	7,803,168 B2	9/2010	Gifford et al.
7,566,319 B2	7/2009	McAuley et al.	7,806,871 B2	10/2010	Li et al.
7,569,052 B2	8/2009	Phan et al.	7,811,265 B2	10/2010	Hering et al.
7,582,111 B2	9/2009	Krolik et al.	7,811,281 B1	10/2010	Rentrop
7,584,004 B2	9/2009	Caparso et al.	7,811,313 B2	10/2010	Mon et al.
7,585,835 B2	9/2009	Hill et al.	7,816,511 B2	10/2010	Kawashima et al.
7,591,996 B2	9/2009	Hwang et al.	7,818,053 B2	10/2010	Kassab
7,597,704 B2	10/2009	Frazier et al.	7,819,866 B2	10/2010	Bednarek
			7,822,460 B2	10/2010	Halperin et al.
			7,828,837 B2	11/2010	Khoury
			7,832,407 B2	11/2010	Gertner
			7,833,220 B2	11/2010	Mon et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

7,837,676 B2	11/2010	Sinelnikov et al.	8,187,261 B2	5/2012	Watson
7,837,720 B2	11/2010	Mon	8,190,238 B2	5/2012	Moll et al.
7,841,978 B2	11/2010	Gertner	8,192,053 B2	6/2012	Owen et al.
7,846,157 B2	12/2010	Kozel	8,198,611 B2	6/2012	LaFontaine et al.
7,846,160 B2	12/2010	Payne et al.	8,214,056 B2	7/2012	Hoffer et al.
7,846,172 B2	12/2010	Makower	8,221,407 B2	7/2012	Phan et al.
7,849,860 B2	12/2010	Makower et al.	8,226,637 B2	7/2012	Satake
7,850,685 B2	12/2010	Kunis et al.	8,231,617 B2	7/2012	Satake
7,853,333 B2	12/2010	Demarais	8,241,217 B2	8/2012	Chiang et al.
7,854,734 B2	12/2010	Biggs et al.	8,257,724 B2	9/2012	Cromack et al.
7,857,756 B2	12/2010	Warren et al.	8,257,725 B2	9/2012	Cromack et al.
7,862,565 B2	1/2011	Eder et al.	8,260,397 B2	9/2012	Ruff et al.
7,863,897 B2	1/2011	Slocum, Jr. et al.	8,263,104 B2	9/2012	Ho et al.
7,869,854 B2	1/2011	Shachar et al.	8,273,023 B2	9/2012	Razavi
7,873,417 B2	1/2011	Demarais et al.	8,277,379 B2	10/2012	Lau et al.
7,887,538 B2	2/2011	Bleich et al.	8,287,524 B2	10/2012	Siegel
7,894,905 B2	2/2011	Pless et al.	8,287,532 B2	10/2012	Carroll et al.
7,896,873 B2	3/2011	Hiller et al.	8,292,881 B2	10/2012	Brannan et al.
7,901,400 B2	3/2011	Wham et al.	8,293,703 B2	10/2012	Averback et al.
7,901,402 B2	3/2011	Jones et al.	8,295,902 B2	10/2012	Salahieh et al.
7,901,420 B2	3/2011	Dunn	8,295,912 B2	10/2012	Gertner
7,905,862 B2	3/2011	Sampson	8,308,722 B2	11/2012	Ormsby et al.
7,918,850 B2	4/2011	Govari et al.	8,317,776 B2	11/2012	Ferren et al.
7,927,370 B2	4/2011	Webler et al.	8,317,810 B2	11/2012	Stangenes et al.
7,937,143 B2	5/2011	Demarais et al.	8,329,179 B2	12/2012	Ni et al.
7,938,830 B2	5/2011	Saadat et al.	8,336,705 B2	12/2012	Okahisa
7,942,874 B2	5/2011	Eder et al.	8,343,031 B2	1/2013	Gertner
7,942,928 B2	5/2011	Webler et al.	8,343,145 B2	1/2013	Brannan
7,946,976 B2	5/2011	Gertner	8,347,891 B2	1/2013	Demarais et al.
7,950,397 B2	5/2011	Thapliyal et al.	8,353,945 B2	1/2013	Andreas et al.
7,955,293 B2	6/2011	Nita et al.	8,364,237 B2	1/2013	Stone et al.
7,956,613 B2	6/2011	Wald	8,366,615 B2	2/2013	Razavi
7,959,627 B2	6/2011	Utley et al.	8,382,697 B2	2/2013	Brenneman et al.
7,962,854 B2	6/2011	Vance et al.	8,388,680 B2	3/2013	Starksen et al.
7,967,782 B2	6/2011	Laufer et al.	8,396,548 B2	3/2013	Perry et al.
7,967,808 B2	6/2011	Fitzgerald et al.	8,398,629 B2	3/2013	Thistle
7,972,327 B2	7/2011	Eberl et al.	8,401,667 B2	3/2013	Gustus et al.
7,972,330 B2	7/2011	Alejandro et al.	8,403,881 B2	3/2013	Ferren et al.
7,983,751 B2	7/2011	Zdeblick et al.	8,406,877 B2	3/2013	Smith et al.
8,001,976 B2	8/2011	Gertner	8,409,172 B2	4/2013	Moll et al.
8,007,440 B2	8/2011	Magnin et al.	8,409,193 B2	4/2013	Young et al.
8,012,147 B2	9/2011	Lafontaine	8,409,195 B2	4/2013	Young
8,019,435 B2	9/2011	Hastings et al.	8,418,362 B2	4/2013	Zerfas et al.
8,021,362 B2	9/2011	Deem et al.	8,452,988 B2	5/2013	Wang
8,021,413 B2	9/2011	Dierking et al.	8,454,594 B2	6/2013	Demarais et al.
8,025,661 B2	9/2011	Arnold et al.	8,460,358 B2	6/2013	Andreas et al.
8,027,718 B2	9/2011	Spinner et al.	8,465,452 B2	6/2013	Kassab
8,031,927 B2	10/2011	Karl et al.	8,469,919 B2	6/2013	Ingle et al.
8,033,284 B2	10/2011	Porter et al.	8,473,067 B2	6/2013	Hastings et al.
8,048,144 B2	11/2011	Thistle et al.	8,480,663 B2	7/2013	Ingle et al.
8,052,636 B2	11/2011	Moll et al.	8,485,992 B2	7/2013	Griffin et al.
8,052,700 B2	11/2011	Dunn	8,486,060 B2	7/2013	Kotmel et al.
8,062,289 B2	11/2011	Babaev	8,486,063 B2	7/2013	Werneth et al.
8,075,580 B2	12/2011	Makower	8,488,591 B2	7/2013	Miali et al.
8,080,006 B2	12/2011	Lafontaine et al.	2001/0007070 A1	7/2001	Stewart et al.
8,088,127 B2	1/2012	Mayse et al.	2001/0039419 A1	11/2001	Francischelli et al.
8,116,883 B2	2/2012	Williams et al.	2002/0022864 A1	2/2002	Mahvi et al.
8,119,183 B2	2/2012	O'Donoghue et al.	2002/0042639 A1	4/2002	Murphy-Chutorian et al.
8,120,518 B2	2/2012	Jang et al.	2002/0045811 A1	4/2002	Kittrell et al.
8,123,741 B2	2/2012	Marrouche et al.	2002/0045890 A1	4/2002	Celliers et al.
8,128,617 B2	3/2012	Bencini et al.	2002/0062146 A1	5/2002	Makower et al.
8,131,371 B2	3/2012	Demarais et al.	2002/0065542 A1	5/2002	Lax et al.
8,131,372 B2	3/2012	Levin et al.	2002/0087151 A1	7/2002	Mody et al.
8,131,382 B2	3/2012	Asada	2002/0095197 A1	7/2002	Lardo et al.
8,137,274 B2	3/2012	Weng et al.	2002/0107536 A1	8/2002	Hussein
8,140,170 B2	3/2012	Rezai et al.	2002/0147480 A1	10/2002	Mamayek
8,143,316 B2	3/2012	Ueno	2002/0169444 A1	11/2002	Mest et al.
8,145,316 B2	3/2012	Deem et al.	2002/0198520 A1	12/2002	Coen et al.
8,145,317 B2	3/2012	Demarais et al.	2003/0018362 A1*	1/2003	Fellows et al. 607/5
8,150,518 B2	4/2012	Levin et al.	2003/0065317 A1	4/2003	Rudie et al.
8,150,519 B2	4/2012	Demarais et al.	2003/0092995 A1	5/2003	Thompson
8,150,520 B2	4/2012	Demarais et al.	2003/0139689 A1	7/2003	Shturman et al.
8,152,830 B2	4/2012	Gumm	2003/0195501 A1	10/2003	Sherman et al.
8,162,933 B2	4/2012	Francischelli et al.	2003/0199747 A1	10/2003	Michlitsch et al.
8,175,711 B2	5/2012	Demarais et al.	2004/0010118 A1	1/2004	Zerhusen et al.
			2004/0019348 A1	1/2004	Stevens et al.
			2004/0024371 A1	2/2004	Plicchi et al.
			2004/0043030 A1	3/2004	Griffiths et al.
			2004/0064090 A1	4/2004	Keren et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

2004/0073206 A1	4/2004	Foley et al.	2006/0089638 A1	4/2006	Carmel et al.
2004/0088002 A1	5/2004	Boyle et al.	2006/0095096 A1	5/2006	DeBenedictis et al.
2004/0093055 A1	5/2004	Bartorelli et al.	2006/0106375 A1	5/2006	Werneth et al.
2004/0106871 A1	6/2004	Hunyor et al.	2006/0142790 A1	6/2006	Gertner
2004/0117032 A1	6/2004	Roth	2006/0147492 A1	7/2006	Hunter et al.
2004/0147915 A1	7/2004	Hasebe	2006/0167106 A1	7/2006	Zhang et al.
2004/0162555 A1	8/2004	Farley et al.	2006/0167498 A1	7/2006	DiLorenzo
2004/0167506 A1	8/2004	Chen	2006/0171895 A1	8/2006	Bucay-Couto
2004/0186356 A1	9/2004	O'Malley et al.	2006/0184221 A1	8/2006	Stewart et al.
2004/0187875 A1	9/2004	He et al.	2006/0195139 A1	8/2006	Gertner
2004/0193211 A1	9/2004	Voegele et al.	2006/0206150 A1	9/2006	Demarais et al.
2004/0220556 A1	11/2004	Cooper et al.	2006/0224153 A1	10/2006	Fischell et al.
2004/0243022 A1	12/2004	Carney et al.	2006/0239921 A1	10/2006	Mangat et al.
2004/0253304 A1	12/2004	Gross et al.	2006/0240070 A1	10/2006	Cromack et al.
2004/0267250 A1	12/2004	Yon et al.	2006/0247266 A1	11/2006	Yamada et al.
2005/0010095 A1	1/2005	Stewart et al.	2006/0247760 A1	11/2006	Ganesan et al.
2005/0015125 A1	1/2005	Mioduski et al.	2006/0263393 A1	11/2006	Demopulos et al.
2005/0080374 A1	4/2005	Esch et al.	2006/0269555 A1	11/2006	Salcedo et al.
2005/0129616 A1	6/2005	Salcedo et al.	2006/0271111 A1	11/2006	Demarais et al.
2005/0137180 A1	6/2005	Robinson et al.	2006/0287644 A1	12/2006	Inganas et al.
2005/0143817 A1	6/2005	Hunter et al.	2007/0016184 A1	1/2007	Cropper et al.
2005/0148842 A1	7/2005	Wang et al.	2007/0016274 A1	1/2007	Boveja et al.
2005/0149069 A1	7/2005	Bertolero et al.	2007/0027390 A1	2/2007	Maschke et al.
2005/0149080 A1	7/2005	Hunter et al.	2007/0043077 A1	2/2007	Mewshaw et al.
2005/0149158 A1	7/2005	Hunter et al.	2007/0043409 A1	2/2007	Brian et al.
2005/0149173 A1	7/2005	Hunter et al.	2007/0049924 A1	3/2007	Rahn
2005/0149175 A1	7/2005	Hunter et al.	2007/0066972 A1	3/2007	Ormsby et al.
2005/0154277 A1	7/2005	Tang et al.	2007/0073151 A1	3/2007	Lee
2005/0154445 A1	7/2005	Hunter et al.	2007/0093710 A1	4/2007	Maschke
2005/0154453 A1	7/2005	Hunter et al.	2007/0100405 A1	5/2007	Thompson et al.
2005/0154454 A1	7/2005	Hunter et al.	2007/0106247 A1	5/2007	Burnett et al.
2005/0165389 A1	7/2005	Swain et al.	2007/0112327 A1	5/2007	Yun et al.
2005/0165391 A1	7/2005	Maguire et al.	2007/0118107 A1	5/2007	Francischelli et al.
2005/0165467 A1	7/2005	Hunter et al.	2007/0129760 A1	6/2007	Demarais et al.
2005/0165488 A1	7/2005	Hunter et al.	2007/0129761 A1	6/2007	Demarais et al.
2005/0175661 A1	8/2005	Hunter et al.	2007/0135875 A1	6/2007	Demarais et al.
2005/0175662 A1	8/2005	Hunter et al.	2007/0149963 A1	6/2007	Matsukuma et al.
2005/0175663 A1	8/2005	Hunter et al.	2007/0162109 A1	7/2007	Davila et al.
2005/0177103 A1	8/2005	Hunter et al.	2007/0173805 A1	7/2007	Weinberg et al.
2005/0177225 A1	8/2005	Hunter et al.	2007/0179496 A1	8/2007	Swoyer et al.
2005/0181004 A1	8/2005	Hunter et al.	2007/0203480 A1	8/2007	Mody et al.
2005/0181008 A1	8/2005	Hunter et al.	2007/0207186 A1	9/2007	Scanlon et al.
2005/0181011 A1	8/2005	Hunter et al.	2007/0208134 A1	9/2007	Hunter et al.
2005/0181977 A1	8/2005	Hunter et al.	2007/0208210 A1	9/2007	Gelfand et al.
2005/0182479 A1	8/2005	Bonsignore et al.	2007/0208256 A1	9/2007	Marilla
2005/0183728 A1	8/2005	Hunter et al.	2007/0208301 A1	9/2007	Evard et al.
2005/0186242 A1	8/2005	Hunter et al.	2007/0219576 A1	9/2007	Cangialosi
2005/0186243 A1	8/2005	Hunter et al.	2007/0225781 A1	9/2007	Saadat et al.
2005/0191331 A1	9/2005	Hunter et al.	2007/0233170 A1	10/2007	Gertner
2005/0203410 A1	9/2005	Jenkins	2007/0239062 A1	10/2007	Chopra et al.
2005/0209587 A1	9/2005	Joye et al.	2007/0248639 A1	10/2007	Demopulos et al.
2005/0214205 A1	9/2005	Salcedo et al.	2007/0249703 A1	10/2007	Mewshaw et al.
2005/0214207 A1	9/2005	Salcedo et al.	2007/0254833 A1	11/2007	Hunter et al.
2005/0214208 A1	9/2005	Salcedo et al.	2007/0265687 A1	11/2007	Deem et al.
2005/0214209 A1	9/2005	Salcedo et al.	2007/0278103 A1	12/2007	Hoerr et al.
2005/0214210 A1	9/2005	Salcedo et al.	2007/0282302 A1	12/2007	Wachsman et al.
2005/0214268 A1	9/2005	Cavanagh et al.	2007/0292411 A1	12/2007	Salcedo et al.
2005/0228286 A1	10/2005	Messerly et al.	2007/0293782 A1	12/2007	Marino
2005/0228415 A1	10/2005	Gertner	2007/0299043 A1	12/2007	Hunter et al.
2005/0228460 A1	10/2005	Levin et al.	2008/0004673 A1	1/2008	Rossing et al.
2005/0232921 A1	10/2005	Rosen et al.	2008/0009927 A1	1/2008	Vilims
2005/0234312 A1	10/2005	Suzuki et al.	2008/0015501 A1	1/2008	Gertner
2005/0245862 A1	11/2005	Seward	2008/0021408 A1	1/2008	Jacobsen et al.
2005/0251116 A1	11/2005	Steinke et al.	2008/0033049 A1	2/2008	Mewshaw
2005/0252553 A1	11/2005	Ginggen	2008/0039746 A1	2/2008	Hissong et al.
2005/0256398 A1	11/2005	Hastings et al.	2008/0039830 A1	2/2008	Munger et al.
2005/0267556 A1	12/2005	Shuros et al.	2008/0051454 A1	2/2008	Wang
2005/0288730 A1	12/2005	Deem et al.	2008/0064957 A1	3/2008	Spence
2006/0004323 A1	1/2006	Chang et al.	2008/0071269 A1	3/2008	Hilario et al.
2006/0018949 A1	1/2006	Ammon et al.	2008/0071306 A1	3/2008	Gertner
2006/0024564 A1	2/2006	Manclaw	2008/0082109 A1	4/2008	Moll et al.
2006/0025765 A1	2/2006	Landman et al.	2008/0086072 A1	4/2008	Bonutti et al.
2006/0062786 A1	3/2006	Salcedo et al.	2008/0091193 A1	4/2008	Kauphusman et al.
2006/0083194 A1	4/2006	Dhrimaj et al.	2008/0097251 A1	4/2008	Babaev
2006/0089637 A1	4/2006	Werneth et al.	2008/0097426 A1	4/2008	Root et al.
			2008/0108867 A1	5/2008	Zhou
			2008/0119879 A1	5/2008	Brenneman et al.
			2008/0125772 A1	5/2008	Stone et al.
			2008/0132450 A1	6/2008	Lee et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

2008/0140002 A1	6/2008	Ramzipoor et al.	2010/0048983 A1	2/2010	Ball et al.
2008/0147002 A1	6/2008	Gertner	2010/0049099 A1	2/2010	Thapliyal et al.
2008/0161662 A1	7/2008	Golijanin et al.	2010/0049186 A1	2/2010	Ingle et al.
2008/0161717 A1	7/2008	Gertner	2010/0049188 A1	2/2010	Nelson et al.
2008/0161801 A1	7/2008	Steinke et al.	2010/0049191 A1	2/2010	Habib et al.
2008/0171974 A1	7/2008	Lafontaine et al.	2010/0049283 A1	2/2010	Johnson
2008/0172035 A1	7/2008	Starksen et al.	2010/0069837 A1	3/2010	Rassat et al.
2008/0172104 A1	7/2008	Kieval et al.	2010/0076299 A1	3/2010	Gustus et al.
2008/0188912 A1	8/2008	Stone et al.	2010/0076425 A1	3/2010	Carroux
2008/0188913 A1	8/2008	Stone et al.	2010/0087782 A1	4/2010	Ghaffari et al.
2008/0208162 A1	8/2008	Joshi	2010/0106005 A1	4/2010	Karczmar et al.
2008/0208169 A1	8/2008	Boyle et al.	2010/0114244 A1	5/2010	Manda et al.
2008/0213331 A1	9/2008	Gelfand et al.	2010/0130836 A1	5/2010	Malchano et al.
2008/0215117 A1	9/2008	Gross	2010/0137860 A1	6/2010	Demarais et al.
2008/0221448 A1	9/2008	Khuri-Yakub et al.	2010/0137952 A1	6/2010	Demarais et al.
2008/0234790 A1	9/2008	Bayer et al.	2010/0160903 A1	6/2010	Krespi
2008/0243091 A1	10/2008	Humphreys et al.	2010/0160906 A1	6/2010	Jarrard
2008/0245371 A1	10/2008	Gruber	2010/0168624 A1	7/2010	Sliwa
2008/0249525 A1	10/2008	Lee et al.	2010/0168731 A1	7/2010	Wu et al.
2008/0249547 A1	10/2008	Dunn	2010/0168739 A1	7/2010	Wu et al.
2008/0255550 A1	10/2008	Bell	2010/0174282 A1	7/2010	Demarais et al.
2008/0255642 A1	10/2008	Zarins et al.	2010/0191112 A1	7/2010	Demarais et al.
2008/0262489 A1	10/2008	Steinke	2010/0191232 A1	7/2010	Boveda
2008/0275484 A1	11/2008	Gertner	2010/0217162 A1	8/2010	Hissong et al.
2008/0281312 A1	11/2008	Werneth et al.	2010/0222786 A1	9/2010	Kassab
2008/0281347 A1	11/2008	Gertner	2010/0222851 A1	9/2010	Deem et al.
2008/0287918 A1	11/2008	Rosenman et al.	2010/0222854 A1	9/2010	Demarais et al.
2008/0294037 A1	11/2008	Richter	2010/0228122 A1	9/2010	Keenan et al.
2008/0300618 A1	12/2008	Gertner	2010/0249604 A1	9/2010	Hastings et al.
2008/0312644 A1	12/2008	Fourkas et al.	2010/0249773 A1	9/2010	Clark et al.
2008/0312673 A1	12/2008	Viswanathan et al.	2010/0256616 A1	10/2010	Katoh et al.
2008/0317818 A1	12/2008	Griffith et al.	2010/0268217 A1	10/2010	Habib
2009/0018486 A1	1/2009	Goren et al.	2010/0268307 A1	10/2010	Demarais et al.
2009/0018609 A1	1/2009	DiLorenzo	2010/0284927 A1	11/2010	Lu et al.
2009/0024194 A1	1/2009	Arcot-Krishnamurthy et al.	2010/0286684 A1	11/2010	Hata et al.
2009/0030312 A1	1/2009	Hadjicostis	2010/0298821 A1	11/2010	Garbagnati
2009/0036948 A1	2/2009	Levin et al.	2010/0305036 A1	12/2010	Barnes et al.
2009/0043372 A1	2/2009	Northrop et al.	2010/0312141 A1	12/2010	Keast et al.
2009/0054082 A1	2/2009	Kim et al.	2010/0324472 A1	12/2010	Wulfman
2009/0062873 A1	3/2009	Wu et al.	2011/0009750 A1	1/2011	Taylor et al.
2009/0069671 A1	3/2009	Anderson	2011/0021976 A1	1/2011	Li et al.
2009/0076409 A1	3/2009	Wu et al.	2011/0034832 A1	2/2011	Cioanta et al.
2009/0088735 A1	4/2009	Abboud et al.	2011/0040324 A1	2/2011	McCarthy et al.
2009/0105631 A1	4/2009	Kieval	2011/0044942 A1	2/2011	Puri et al.
2009/0112202 A1	4/2009	Young	2011/0060324 A1	3/2011	Wu et al.
2009/0118620 A1	5/2009	Tgavalekos et al.	2011/0071400 A1	3/2011	Hastings et al.
2009/0118726 A1	5/2009	Auth et al.	2011/0071401 A1	3/2011	Hastings et al.
2009/0125099 A1	5/2009	Weber et al.	2011/0077498 A1	3/2011	McDaniel
2009/0131798 A1	5/2009	Minar	2011/0092781 A1	4/2011	Gertner
2009/0143640 A1	6/2009	Saadat et al.	2011/0092880 A1	4/2011	Gertner
2009/0156988 A1	6/2009	Ferren et al.	2011/0104061 A1	5/2011	Seward
2009/0157057 A1	6/2009	Ferren et al.	2011/0112400 A1	5/2011	Emery et al.
2009/0157161 A1	6/2009	Desai et al.	2011/0118600 A1	5/2011	Gertner
2009/0171333 A1	7/2009	Hon	2011/0118726 A1	5/2011	De La Rama et al.
2009/0192558 A1	7/2009	Whitehurst et al.	2011/0130708 A1	6/2011	Perry et al.
2009/0198223 A1	8/2009	Thilwind et al.	2011/0137155 A1	6/2011	Weber et al.
2009/0203962 A1	8/2009	Miller et al.	2011/0144479 A1	6/2011	Hastings et al.
2009/0203993 A1	8/2009	Mangat et al.	2011/0146673 A1	6/2011	Keast et al.
2009/0204170 A1	8/2009	Hastings et al.	2011/0166499 A1	7/2011	Demarais et al.
2009/0210953 A1	8/2009	Moyer et al.	2011/0178570 A1	7/2011	Demarais
2009/0216317 A1	8/2009	Cromack et al.	2011/0178584 A1*	7/2011	Parmer A61B 18/1485 607/102
2009/0221955 A1	9/2009	Babaev	2011/0200171 A1	8/2011	Beetel et al.
2009/0226429 A1	9/2009	Salcedo et al.	2011/0202098 A1	8/2011	Demarais et al.
2009/0240249 A1	9/2009	Chan et al.	2011/0207758 A1	8/2011	Sobotka et al.
2009/0247933 A1	10/2009	Maor et al.	2011/0208096 A1	8/2011	Demarais et al.
2009/0247966 A1	10/2009	Gunn et al.	2011/0257523 A1	10/2011	Hastings et al.
2009/0248012 A1	10/2009	Maor et al.	2011/0257564 A1	10/2011	Demarais et al.
2009/0253974 A1	10/2009	Rahme	2011/0257622 A1	10/2011	Salahieh et al.
2009/0264755 A1	10/2009	Chen et al.	2011/0257641 A1	10/2011	Hastings et al.
2009/0270850 A1	10/2009	Zhou et al.	2011/0257642 A1	10/2011	Griggs, III
2009/0281533 A1	11/2009	Ingle et al.	2011/0263921 A1	10/2011	Vrba et al.
2009/0287137 A1	11/2009	Crowley	2011/0264011 A1	10/2011	Wu et al.
2009/0318749 A1	12/2009	Stolen et al.	2011/0264075 A1	10/2011	Leung et al.
2010/0009267 A1	1/2010	Chase et al.	2011/0264086 A1	10/2011	Ingle
2010/0030061 A1	2/2010	Canfield et al.	2011/0264116 A1	10/2011	Kocur et al.
			2011/0270238 A1	11/2011	Rizq et al.
			2011/0306851 A1	12/2011	Wang
			2011/0319809 A1	12/2011	Smith

(56)

References Cited

U.S. PATENT DOCUMENTS

2012/0029496 A1 2/2012 Smith
 2012/0029500 A1 2/2012 Jenson
 2012/0029505 A1 2/2012 Jenson
 2012/0029509 A1 2/2012 Smith
 2012/0029510 A1 2/2012 Haverkost
 2012/0029511 A1 2/2012 Smith et al.
 2012/0029512 A1 2/2012 Willard et al.
 2012/0029513 A1 2/2012 Smith et al.
 2012/0059241 A1 3/2012 Hastings et al.
 2012/0059286 A1 3/2012 Hastings et al.
 2012/0065506 A1 3/2012 Smith
 2012/0065554 A1 3/2012 Pikus
 2012/0095461 A1 4/2012 Herscher et al.
 2012/0101413 A1 4/2012 Beetel et al.
 2012/0101490 A1 4/2012 Smith
 2012/0101538 A1 4/2012 Ballakur et al.
 2012/0109021 A1 5/2012 Hastings et al.
 2012/0116382 A1 5/2012 Ku et al.
 2012/0116383 A1 5/2012 Mauch et al.
 2012/0116392 A1 5/2012 Willard
 2012/0116438 A1 5/2012 Salahieh et al.
 2012/0116486 A1 5/2012 Naga et al.
 2012/0123243 A1 5/2012 Hastings
 2012/0123258 A1 5/2012 Willard
 2012/0123261 A1 5/2012 Jenson et al.
 2012/0123303 A1 5/2012 Sogard et al.
 2012/0123406 A1 5/2012 Edmunds et al.
 2012/0130289 A1 5/2012 Demarais et al.
 2012/0130345 A1 5/2012 Levin et al.
 2012/0130359 A1 5/2012 Turovskiy
 2012/0130360 A1 5/2012 Buckley et al.
 2012/0130362 A1 5/2012 Hastings et al.
 2012/0130368 A1 5/2012 Jenson
 2012/0130458 A1 5/2012 Ryba et al.
 2012/0136344 A1 5/2012 Buckley et al.
 2012/0136349 A1 5/2012 Hastings
 2012/0136350 A1 5/2012 Goshgarian et al.
 2012/0136417 A1 5/2012 Buckley et al.
 2012/0136418 A1 5/2012 Buckley et al.
 2012/0143181 A1 6/2012 Demarais et al.
 2012/0143293 A1 6/2012 Mauch et al.
 2012/0143294 A1 6/2012 Clark et al.
 2012/0150267 A1 6/2012 Buckley et al.
 2012/0157986 A1 6/2012 Stone et al.
 2012/0157987 A1 6/2012 Steinke et al.
 2012/0157988 A1 6/2012 Stone et al.
 2012/0157989 A1 6/2012 Stone et al.
 2012/0157992 A1 6/2012 Smith et al.
 2012/0157993 A1 6/2012 Jenson et al.
 2012/0158101 A1 6/2012 Stone et al.
 2012/0158104 A1 6/2012 Huynh et al.
 2012/0172837 A1 7/2012 Demarais et al.
 2012/0172870 A1 7/2012 Jenson et al.
 2012/0184952 A1 7/2012 Jenson et al.
 2012/0197198 A1 8/2012 Demarais et al.
 2012/0197252 A1 8/2012 Deem et al.
 2012/0232409 A1 9/2012 Stahmann et al.
 2012/0265066 A1 10/2012 Crow et al.
 2012/0265198 A1 10/2012 Crow et al.
 2013/0012844 A1 1/2013 Demarais et al.
 2013/0012866 A1 1/2013 Deem et al.
 2013/0012867 A1 1/2013 Demarais et al.
 2013/0013024 A1 1/2013 Levin et al.
 2013/0023865 A1 1/2013 Steinke et al.
 2013/0035681 A1 2/2013 Subramaniam et al.
 2013/0066316 A1 3/2013 Steinke et al.
 2013/0085489 A1 4/2013 Fain et al.
 2013/0090563 A1 4/2013 Weber
 2013/0090578 A1 4/2013 Smith et al.
 2013/0090647 A1 4/2013 Smith
 2013/0090649 A1 4/2013 Smith et al.
 2013/0090650 A1 4/2013 Jenson et al.
 2013/0090651 A1 4/2013 Smith
 2013/0090652 A1 4/2013 Jenson
 2013/0096550 A1 4/2013 Hill

2013/0096553 A1 4/2013 Hill et al.
 2013/0096554 A1 4/2013 Groff et al.
 2013/0096604 A1 4/2013 Hanson et al.
 2013/0110106 A1 5/2013 Richardson
 2013/0116687 A1 5/2013 Willard
 2013/0165764 A1 6/2013 Scheuermann et al.
 2013/0165844 A1 6/2013 Shuros et al.
 2013/0165916 A1 6/2013 Mathur et al.
 2013/0165917 A1 6/2013 Mathur et al.
 2013/0165920 A1 6/2013 Weber et al.
 2013/0165923 A1 6/2013 Mathur et al.
 2013/0165924 A1 6/2013 Mathur et al.
 2013/0165925 A1 6/2013 Mathur et al.
 2013/0165926 A1 6/2013 Mathur et al.
 2013/0165990 A1 6/2013 Mathur et al.
 2013/0172815 A1 7/2013 Perry et al.
 2013/0172872 A1 7/2013 Subramaniam et al.
 2013/0172877 A1 7/2013 Subramaniam et al.
 2013/0172878 A1 7/2013 Smith
 2013/0172879 A1 7/2013 Sutermeister
 2013/0172880 A1 7/2013 Willard
 2013/0172881 A1 7/2013 Hill et al.

FOREIGN PATENT DOCUMENTS

EP 1180004 A1 2/2002
 EP 1335677 B1 8/2003
 EP 1874211 A2 1/2008
 EP 1906853 A2 4/2008
 EP 1961394 A2 8/2008
 EP 1620156 B1 7/2009
 EP 2076193 A2 7/2009
 EP 2091455 A2 8/2009
 EP 2197533 A1 6/2010
 EP 2208506 A1 7/2010
 EP 1579889 B1 8/2010
 EP 2092957 B1 1/2011
 EP 2349044 A1 8/2011
 EP 2027882 B1 10/2011
 EP 2378956 A2 10/2011
 EP 2037840 B1 12/2011
 EP 2204134 B1 4/2012
 EP 2320821 B1 10/2012
 GB 2456301 A 7/2009
 WO 9858588 A1 12/1998
 WO 9900060 A1 1/1999
 WO 0047118 A1 8/2000
 WO 03026525 A1 4/2003
 WO 2004100813 A2 11/2004
 WO 2004110258 A2 12/2004
 WO 2006044794 A2 4/2006
 WO 2006105121 A2 10/2006
 WO 2008014465 A2 1/2008
 WO 2009121017 A1 10/2009
 WO 2010067360 A2 6/2010
 WO 2010102310 A2 9/2010
 WO 2011005901 A2 1/2011
 WO 2011053757 A1 5/2011
 WO 2011053772 A1 5/2011
 WO 2011091069 A1 7/2011
 WO 2011130534 A2 10/2011
 WO 2012019156 A1 2/2012
 WO 2012075156 A1 6/2012
 WO 2013049601 A2 4/2013

OTHER PUBLICATIONS

Van Den Berg, "Light echoes image the human body," OLE, Oct. 2001, p. 35-37.
 "IntraLuminal: Products," IntraLuminal Therapeutics, Inc., 2003, p. 1-9.
 "Laser Catheter to Aid Coronary Surgery," TechTalk: MIT, Jan. 9, 1991, p. 1-4.
 "Optical Coherence Tomography: Advantages of OCT," LightLab Imaging Technology.
 "Optical Coherence Tomography: Image Gallery Cardiovascular Procedures," LightLab Imaging Technology.

(56)

References Cited

OTHER PUBLICATIONS

- “Optical Coherence Tomography: LightLab Imaging Starts US Cardiology Clinical Investigations,” LightLab Imaging Technology, 2002.
- “Optical Coherence Tomography: LightLab Sees Bright Prospects for Cardiac Application of OCT Technology,” LightLab Imaging Technology, 2001, vol. 27, No. 35.
- “Optical Coherence Tomography: What is OCT?,” LightLab Imaging Technology.
- “Optical Coherence Tomography: Why Use OCT?,” LightLab Imaging Technology.
- “Products—Functional Measurement,” VOLCANO Functional Measurement Products US, Mar. 24, 2003, p. 1-2.
- Brown et al., “Radiofrequency capacitive heaters: the effect of coupling medium resistivity on power absorption along a mouse leg,” *Physics in Medicine and Biology*, 1993, p. 1-12, vol. 38.
- Carrington, “Future of CVI: It’s all about plaque: Identification of vulnerable lesions, not ‘rusty pipes,’ could become cornerstone of preventive cardiology,” *Diagnostic Imaging*, 2001, p. 1-8.
- Chen et al., “Percutaneous pulmonary artery denervation completely abolishes experimental pulmonary arterial hypertension in vivo,” *EuroIntervention*, 2013, p. 1-8.
- Cimino, “Preventing plaque attack,” *Mass High Tech*, 2001, p. 1-2.
- Dahm et al., “Relation of Degree of Laser Debulking of In-Stent Restenosis as a Predictor of Restenosis Rate,” *The American Journal of Cardiology*, 2002, p. 68-70, vol. 90.
- De Korte et al., “Characterization of Plaque Components With Intravascular Ultrasound Elastography in Human Femoral and Coronary Arteries in Vitro,” *Circulation*, Aug. 8, 2000, p. 617-623.
- Durney et al., “Radiofrequency Radiation Dosimetry Handbook,” Oct. 1986, p. 1-2, Fourth Edition.
- Durney et al., “Radiofrequency Radiation Dosimetry Handbook: Contents,” Oct. 1986, p. 1-5, Fourth Edition.
- Fournier-Desseux et al., “Assessment of 1-lead and 2-lead electrode patterns in electrical impedance endotomography,” *Physiological Measurement*, 2005, p. 337-349. Vol. 26, Institute of Physics Publishing.
- Fram et al., “Feasibility of Radiofrequency Powered, Thermal Balloon Ablation of Atrioventricular Bypass Tracts Via the Coronary Sinus: In Vivo Canine Studies,” *PACE*, Aug. 1995, p. 1518-1530, vol. 18.
- Fram et al., “Low Pressure Radiofrequency Balloon Angioplasty: Evaluation in Porcine Peripheral Arteries,” *JACC*, 1993, p. 1512-1521, vol. 21, No. 6, American College of Cardiology.
- Fujimori et al., “Significant Prevention of In-Stent Restenosis by Evans Blue in Patients with Acute Myocardial Infarction,” *American Heart Association*, 2002.
- Fujita et al., “Sarpogrelate, An Antagonist of 5-HT(2A) Receptor, Treatment Reduces Restenosis After Coronary Stenting,” *American Heart Association*, 2002.
- Gabriel, “Appendix A: Experimental Data,” 1999, p. 1-21.
- Gabriel, “Appendix C: Modeling the frequency dependence of the dielectric properties to a 4 dispersions spectrum,” p. 1-6.
- Gregory et al., “Liquid Core Light Guide for Laser Angioplasty,” *The Journal of Quantum Electronics*, Dec. 1990, p. 2289-2296, vol. 26, No. 12.
- Kaplan et al., “Healing after Arterial Dilatation with Radiofrequency Thermal and Nonthermal Balloon Angioplasty Systems,” *Journal of Investigative Surgery*, 1993, p. 33-52, vol. 6.
- Kolata, “New Studies Question Value of Opening Arteries,” *The New York Times*, Mar. 21, 2004, p. 1-5.
- Konings et al., “Development of an Intravascular Impedance Catheter for Detection of Fatty Lesions in Arteries,” *IEEE Transactions on Medical Imaging*, Aug. 1997, p. 439-446, vol. 16, No. 4.
- Kurtz et al., “Lamellar Refractive Surgery with Scanned Intrastromal Picosecond and Femtosecond Laser Pulses in Animal Eyes,” *Journal of Refractive Surgery*, Sep./Oct. 1998, p. 541-548.
- Lee et al., “Thermal Compression and Molding of Atherosclerotic Vascular Tissue With Use of Radiofrequency Energy: Implications for Radiofrequency Balloon Angioplasty,” *JACC*, 1989, p. 1167-1175, vol. 13, No. 5, American College of Cardiology.
- Lima et al., “Efficacy and Safety of Oral Sirolimus to Treat and Prevent In-Stent Restenosis: A Pilot Study Results,” *American Heart Association*, 2002, p. 2929.
- Lima et al., “Systemic Immunosuppression Inhibits In-Stent Coronary Intimal Proliferation in Renal Transplant Patients,” *American Heart Association*, 2002, p. 2928.
- Morice et al., “A Randomized Comparison of a Sirolimus-Eluting Stent With a Standard Stent for Coronary Revascularization,” *The New England Journal of Medicine*, Jun. 6, 2012, p. 1773-1780, vol. 346, No. 23.
- Muller-Leisse et al., “Effectiveness and Safety of Ultrasonic Atherosclerotic Plaque Ablation: In Vitro Investigation,” *CardioVascular and Interventional Radiology*, 1993, p. 303-307, vol. 16.
- Nair et al., “Regularized Autoregressive Analysis of Intravascular Ultrasound Backscatter: Improvement in Spatial Accuracy of Tissue Maps,” *IEEE Transactions on Ultrasonics*, Apr. 2004, p. 420-431, vol. 51, No. 4.
- Popma et al., “Percutaneous Coronary and Valvular Intervention,” p. 1364-1405.
- Resar et al., “Endoluminal Sealing of Vascular Wall Disruptions With Radiofrequency-Heated Balloon Angioplasty,” *Catheterization and Cardiovascular Diagnosis*, 1993, p. 161-167, vol. 29.
- Romer et al., “Histopathology of Human Coronary Atherosclerosis by Quantifying Its Chemical Composition With Raman Spectroscopy,” *Circulation*, 1998, p. 878-885, vol. 97.
- Schauerte et al., “Catheter Ablation of Cardiac Autonomic Nerves for Prevention of Vagal Atrial Fibrillation,” *Circulation*, 2000, p. 2774-2780, vol. 102.
- Scheller et al., “Intracoronary Paclitaxel Added to Contrast Media Inhibits In-Stent Restenosis of Porcine Coronary Arteries,” *American Heart Association*, 2002, p. 2227.
- Scheller et al., “Potential solutions to the current problem: coated balloon,” *EuroIntervention*, 2008, p. C63-C66, vol. 4 (Supplement C).
- Shaffer, “Scientific basis of laser energy,” *Clinics in Sports Medicine*, 2002, p. 585-598, vol. 21.
- Shmatukha et al., “MRI temperature mapping during thermal balloon angioplasty,” *Physics in Medicine and Biology*, 2006, p. N163-N171, vol. 51.
- Slager et al., “Vaporization of Atherosclerotic Plaques by Spark Erosion,” *J Am Coll Cardiol*, 1985, p. 21-25.
- Stiles et al., “Simulated Characterization of Atherosclerotic Lesions in the Coronary Arteries by Measurement of Bioimpedance,” *IEEE Transactions on Biomedical Engineering*, Jul. 2003, p. 916-921, vol. 50, No. 7.
- Suselbeck et al., “In vivo intravascular electric impedance spectroscopy using a new catheter with integrated microelectrodes,” *Basic Res Cardiol*, 2005, p. 28-34, vol. 100.
- Suselbeck et al., “Intravascular electric impedance spectroscopy of atherosclerotic lesions using a new impedance catheter system,” *Basic Res Cardiol*, 2005, p. 446-452, vol. 100.
- Tepe et al., “Local Delivery of Paclitaxel to Inhibit Restenosis during Angioplasty of the Leg,” *The New England Journal of Medicine*, 2008, p. 689-699, vol. 358.
- CardioVascular Technologies Inc., “Heated Balloon Device Technology,” 11 pages, 2008.
- Strategic Business Development, Inc., “Thermal and Disruptive Angioplasty: A Physician’s Guide,” 8 pages, 1990.
- Zhang et al., “Non-contact Radio-Frequency Ablation for Obtaining Deeper Lesions,” *IEEE Transaction on Biomedical Engineering*, vol. 50, No. 2, 6 pages, Feb 2003.
- Lazebnik et al., “Tissue Strain Analytics Virtual Touch Tissue Imaging and Qualification,” *Siemens Whitepaper*, Oct. 2008, 7 pages.
- Han et al., “Third-Generation Cryosurgery for Primary and Recurrent Prostate Cancer,” *BJU International*, vol. 93, pp. 14-18.
- Zhou et al., “Mechanism Research of Ciyoanalgesia,” *Forefront Publishing Group*, 1995.
- Florete, “Cryoblative Procedure for Back Pain,” *Jacksonville Medicine*, Oct. 1998, 10 pages.

(56)

References Cited

OTHER PUBLICATIONS

- Stevenson, "Irrigated RF Ablation: Power Titration and Fluid Management for Optimal Safety Efficacy," 2005, 4 pages.
- Giliatt et al., "The Cause of Nerve Damage in Acute Compression," *Trans Am Neurol Assoc*, 1974: 99; 71-4.
- Omura et al., "A Mild Acute Compression Induces Neurapraxia in Rat Sciatic Nerve," *The International Journal of Neuroscience*, vol. 114 (12), pp. 1561-1572.
- Baun, "Interaction with Soft Tissue," *Principles of General & Vascular Sonography*, Chapter 2, pp. 23-24, Before Mar. 2012.
- Blue Cross Blue Shield Medical Policy, "Surgery Section—MRI-Guided Focused Ultrasound (MRgFUS) for the Treatment of Uterine Fibroids and Other Tumors," 2005, 5 pages.
- Gentry et al., "Combines 3D Intracardiac Echo and Ultrasound Ablation," *Medical Imaging 2003: Ultrasonic and Signal Processing*, vol. 5035, 2003, pp. 166-173.
- Lafon et al., "Optimizing the Shape of Ultrasound Transducers for Interstitial Thermal Ablations," *MEd Phys*. Mar. 2002; 29(3): 290-7 (abstract only).
- G. Ter Haar, "Ultrasound Focal Beam Surgery," *Ultrasound in Med. & Biol.*, 1995, vol. 21, No. 9, pp. 1089-1100.
- Seip et al., "Transurethral High Intensity Focused Ultrasound: Catheter Based Prototypes and Experimental Results," *IEEE Ultrasonics Symposium Proceeding*, 2000, 4 pages.
- Toytman et al., "Tissue Dissection with Ultrafast Laser Using Extended and Multiple Foci," *SPIE Proceeding, Optical Interactions with Tissues and Cells XXI*, vol. 7562, 2010, 10 pages.
- Zhou et al., "Non-Thermal Ablation of Rabbit Liver VX2 Tumore by Pulsed High Intensity Focused Ultrasound Contrast Agent: Pathological Characteristics," *World Journal of Gastroenterology*, vol. 14(43), Nov. 21, 2008, pp. 6743-6747.

* cited by examiner




Figure 1




Figure 2




Figure 3A




Figure 3B




Figure 4




Figure 5




Figure 6A




Figure 6B




Figure 6C




Figure 6D




Figure 7




Figure 8A




Figure 8B




Figure 9

OFF-WALL ELECTRODE DEVICE AND METHODS FOR NERVE MODULATION

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority under 35 U.S.C. § 119 to U.S. Provisional Application Ser. No. 61/605,599, filed Mar. 1, 2012 and to U.S. Provisional Application Ser. No. 61/545,912, filed Oct. 11, 2011, both of which are herein incorporated by reference.

TECHNICAL FIELD

The present invention relates to methods and apparatuses for modulation of nerves through the walls of blood vessels. Such modulation may include ablation of nerve tissue or other modulation technique.

BACKGROUND

Certain treatments require the temporary or permanent interruption or modification of select nerve function. One example treatment is renal nerve ablation which is sometimes used to treat conditions related to congestive heart failure. The kidneys produce a sympathetic response to congestive heart failure, which, among other effects, increases the undesired retention of water and/or sodium. Ablating some of the nerves running to the kidneys may reduce or eliminate this sympathetic function, which may provide a corresponding reduction in the associated undesired symptoms.

Many nerves (and nervous tissue such as brain tissue), including renal nerves, run along the walls of or in close proximity to blood vessels and thus can be accessed intravascularly through the walls of the blood vessels. In some instances, it may be desirable to ablate perivascular renal nerves using a radio frequency (RF) electrode. However, such a treatment may result in thermal injury to the vessel wall at the electrode and other undesirable side effects such as, but not limited to, blood damage, clotting and/or protein fouling of the electrode. Increased cooling in the region of the nerve ablation may reduce such undesirable side effects.

Therefore, there remains room for improvement and/or alternatives in providing for systems and methods for intravascular nerve modulation.

SUMMARY

The disclosure is directed to several alternative designs, materials and methods of manufacturing medical device structures and assemblies.

Accordingly, some embodiments pertain to a system for nerve modulation through the wall of a blood vessel, comprising an elongate member extending along a central elongate axis and having a proximal end and a distal end, the elongate member having a radially expandable member disposed proximate the distal end, and a tubular sheath cooperatively engaged with the expandable member such that the expandable member is not expanded when in the sheath and can expand when moved out of the sheath, the expandable member comprising a plurality of electrodes and a plurality of spacer struts, each spacer strut configured such that when the expandable member is in an expanded state the spacer strut extends out radially further than the electrodes from the central elongate axis. The elongate member may further comprise an expandable blood vessel occluder dis-

posed under the plurality of electrodes, the occluder having an expanded state such that when the occluder is in the expanded state and the self-expanding member is in the expanded state, there is a gap between each of the plurality of electrodes and the occluder. The expandable member may be self-expanding, being biased to an expanded state or may be balloon-expandable or expandable using some other suitable mechanical means. If the expandable member is balloon-expandable, it may be biased to a non-expanded state. The expandable member may comprise a pair of spacer struts for each electrode, wherein each pair of spacer struts defines a gap in which the corresponding electrode is located. The expandable member may comprise a first set of electrodes and spacer struts and a second set of electrodes and spacer struts and wherein the first set is disposed at a different axial location relative to the second set. In such a case, it may be that none of the electrodes in the first set are at the same radial position as any of the electrodes in the second set. The expandable member may comprise a plurality of sets, each set comprising an electrode and a spacer strut, each set being electrically isolated from the other sets. In one of such sets, an electrode is disposed on an electrode strut, the electrode strut having a free end and a joined end, the joined end of the electrode strut being joined to the spacer strut. Such a set may be made by forming the electrode and the electrode strut from the same precursor to create a monolithic strut/electrode assembly. The electrode may have a perimeter and a first material and further comprising a layer of a second conductive material disposed on a surface of the electrode and wherein the layer does not extend to the perimeter. The electrode may have a first side, a second side and a perimeter therebetween, and further comprising an insulating material on the perimeter. The system may be configured such that when the expandable member is in an expanded state in the blood vessel, there is a shortest path between each electrode and the vessel wall and wherein no element of the system is disposed in the shortest paths.

Some embodiments pertain to a system for nerve modulation through the wall of a blood vessel, comprising an elongate member extending along a central elongate axis and having a proximal end and a distal end, the elongate member having a radially expandable member disposed proximate the distal end and an expandable occlusive member disposed beneath the radially expandable member, and a tubular sheath cooperatively engaged with the expandable member such that the expandable member is not expanded when in the sheath and can expand when moved distally out of the sheath, the expandable member comprising a plurality of electrodes and a plurality of spacer struts, each spacer strut configured such that when the expandable member is in an expanded state the spacer strut extends out radially further than the electrodes from the central elongate axis. The expandable member may have an expanded state and a maximum diameter in the expanded state and wherein the expandable occlusive member is expandable to a diameter of between 40% and 60% of the maximum diameter of the self-expanding member. The expandable occlusive member may have an expanded state such that when the self-expanding member is in the expanded state and the expandable occlusive member is in the expanded state, the electrodes are spaced away from the expandable occlusive member. The expandable occlusive device may include an inflatable balloon. The expandable occlusive device may comprise a self-expanding structure covered with a membrane substantially impervious to blood flow, the self-ex-

panding structure defining a central cavity and the membrane configured to prevent significant blood flow through the central cavity.

Some embodiments pertain to a method of manufacturing a system for nerve modulation, comprising the steps of providing a first elongate flexible member, providing a resilient tubular member having an outer surface, a central cavity and proximal and distal ends, forming spacer struts in the resilient tubular member, fixing the elongate flexible member within the central cavity by joining the proximal end of the resilient tubular member to the elongate flexible member; and subsequent to the step of fixing, forming two cuts in the resilient tubular member, each cut extending from the proximal end to the distal end and from the outer surface to the central cavity along the entire length from the proximal end to the distal end. The method may include the step of forming two cuts, fixing a tubular non-conductive layer over the proximal end of the resilient tubular member, the layer joined to the resilient tubular member and to the first elongate flexible member.

Some embodiments pertain to a system that further includes one or more boundary layer control elements. Such a boundary layer control element may be a trip strut spaced from the vessel wall and downstream of the electrode. The trip strut may cause the blood flow to be more turbulent, thereby increasing heat transfer between the blood and the vessel wall.

Some embodiments pertain to a system where the electrodes have a non-conductive or inert side that faces or is against the vessel wall and an active or conductive side that faces radially inwardly.

The above summary of some example embodiments is not intended to describe each disclosed embodiment or every implementation of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

The invention may be more completely understood in consideration of the following detailed description of various embodiments in connection with the accompanying drawings, in which:

FIG. 1 is a schematic view illustrating a renal nerve modulation system in situ.

FIG. 2 illustrates a distal end of an illustrative renal nerve modulation system.

FIG. 3A is a side view of the illustrative renal nerve modulation system of FIG. 2 in a blood vessel.

FIG. 3B is an end view of the illustrative renal nerve modulation system of FIG. 2 in a blood vessel.

FIG. 4 is a side view of an illustrative renal nerve modulation system in a blood vessel.

FIG. 5 is a side view of an illustrative renal nerve modulation system.

FIG. 6A is a view of an illustrative electrode/strut unit.

FIG. 6B is a view of an illustrative electrode/strut unit.

FIG. 6C is a view of an illustrative electrode/strut unit.

FIG. 6D is a view of an illustrative electrode/strut unit.

FIG. 7 is a view of an illustrative electrode on a strut.

FIG. 8A is a side view of an illustrative renal nerve modulation system in a blood vessel.

FIG. 8B is an end view of the illustrative renal nerve modulation system of FIG. 8B in a blood vessel.

FIG. 9 is an isometric view of the distal portions of an illustrative renal nerve modulation system.

While the invention is amenable to various modifications and alternative forms, specifics thereof have been shown by way of example in the drawings and will be described in

detail. It should be understood, however, that the intention is not to limit aspects of the invention to the particular embodiments described. On the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention.

DETAILED DESCRIPTION

For the following defined terms, these definitions shall be applied, unless a different definition is given in the claims or elsewhere in this specification.

All numeric values are herein assumed to be modified by the term “about”, whether or not explicitly indicated. The term “about” generally refers to a range of numbers that one of skill in the art would consider equivalent to the recited value (i.e., having the same function or result). In many instances, the term “about” may be indicative as including numbers that are rounded to the nearest significant figure.

The recitation of numerical ranges by endpoints includes all numbers within that range (e.g., 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, and 5).

Although some suitable dimensions ranges and/or values pertaining to various components, features and/or specifications are disclosed, one of skill in the art, incited by the present disclosure, would understand desired dimensions, ranges and/or values may deviate from those expressly disclosed.

As used in this specification and the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the content clearly dictates otherwise. As used in this specification and the appended claims, the term “or” is generally employed in its sense including “and/or” unless the content clearly dictates otherwise.

The following detailed description should be read with reference to the drawings in which similar elements in different drawings are numbered the same. The detailed description and the drawings, which are not necessarily to scale, depict illustrative embodiments and are not intended to limit the scope of the invention. The illustrative embodiments depicted are intended only as exemplary. Selected features of any illustrative embodiment may be incorporated into an additional embodiment unless clearly stated to the contrary.

While the devices and methods described herein are discussed relative to renal nerve modulation, it is contemplated that the devices and methods may be used in other applications where nerve modulation and/or ablation are desired.

In some instances, it may be desirable to ablate perivascular renal nerves with deep target tissue heating. However, as energy passes from an electrode to the desired treatment region the energy may heat the fluid and tissue as it passes. As more energy is used, higher temperatures in the surrounding tissues may be achieved, but may result in some negative side effects, such as, but not limited to thermal injury to the vessel wall, blood damage, clotting and/or protein fouling of the electrode. Positioning the electrode away from the vessel wall may provide some degree of passive cooling by allowing blood to flow past the electrode. However, it may be desirable to provide an increased level of cooling. In some instances, a partial occlusion catheter may be used to partially occlude an artery or vessel during nerve ablation. The partial occlusion catheter may increase the velocity of blood flow in a region proximate the desired treatment area while minimally affecting the volume of blood passing, if at all. The increased velocity of blood flow may increase the convective cooling of the blood and tissue

5

surrounding the treatment area and reducing artery wall thermal injury, blood damage, and/or clotting. The renal nerve modulation systems described herein may include other mechanisms to improve convective heat transfer, such as, but not limited to directing flow patterns with surfaces, flushing fluid from a guide catheter or other lumen, or infusing cool fluid.

FIG. 1 is a schematic view of an illustrative renal nerve modulation assembly 10 in situ. Assembly 10 may include one or more conductive element(s) 16 for providing power to renal ablation system 12 disposed within a sheath 14, the details of which can be better seen in subsequent figures. Alternatively, the sheath 14 may take the form of a guide catheter. A proximal end of conductive element 16 may be connected to a control and power element 18, which supplies the necessary electrical energy to activate the one or more electrodes at or near a distal end of the renal ablation system 12. In some instances, return electrode patches 20 may be supplied on the legs or at another conventional location on the patient's body to complete the circuit. The control and power element 18 may include monitoring elements to monitor parameters such as power, temperature, voltage, pulse size and/or shape and other suitable parameters as well as suitable controls for performing the desired procedure. In some instances, the power element 18 may control a radio frequency (RF) electrode. The electrode may be configured to operate at a frequency of approximately 460 kHz. It is contemplated that any desired frequency in the RF range may be used, for example, from 450-500 kHz. It is further contemplated that ranges of frequency outside the RF spectrum may be used as desired, for example, but not limited to ultrasound, microwave, and laser.

FIG. 2 is an illustrative embodiment of a distal end of a renal nerve ablation system 12. The system 12 may include an elongate shaft 21 having a distal end region 22. The distal end region may be fixed to the elongate shaft 21 or may be movable longitudinally with respect thereto. The system 12 may include one or more strut assemblies 24 disposed radially about an inner expansion element 32. The strut assemblies 24 may be attached to the shaft 21 at the proximal and distal ends of the strut assemblies or at only the proximal end of the strut assemblies or only at the distal ends of the strut assemblies. The strut assemblies may be disposed so they expand in a radially symmetric manner from the shaft. In other embodiments, the strut assemblies may expand asymmetrically from the shaft. There may be two, three, four (as shown), or more strut assemblies 24 and they may be spaced equally about the shaft 21 or may be spaced unequally. Each strut assembly 24 may include one, two (as shown) or more spacer struts 26 and an electrode strut 28. An electrode 30 is attached to the electrode strut 28 and may be a separate piece joined to the electrode strut or may be formed with the electrode strut and the strut assembly from a single piece of material to form a monolithic electrode strut 28/electrode 30 assembly. The conductive element(s) 16 are electrically connected to electrode(s) 30. Each electrode may have a separate electrical connection through a conductive element 16 to the controller 18 or there may be a single conductive element 16 common to each electrode 30. Each strut assembly 24 may form a portion of the conductive path to each electrode or a separate conductive path may extend between conductive element 16 and the electrode. Such a separate conductive path may be a separate wire or may be a conductive strip printed or otherwise formed on a strut assembly 24.

The strut assemblies 24 can be collapsed to a low profile state by using, for example, the sheath 14 (other another

6

suitable structure) and may be generally biased to an expanded state as shown. In other embodiments, the strut assemblies may be expanded outwardly using a balloon or other suitable mechanical means. In the expanded state, the spacer struts 26 extend out further radially than the electrode 30 and thus serve to keep the electrode a predetermined distance from the wall of a blood vessel when the system is in use. The inner expansion element 32 serves to partially occlude the vessel. It may, for example, expand to between 40% and 70% or to between 45% and 66% or to between 50% and 60% of the diameter of the system when the strut assemblies 24 are allowed to fully expand when unconstrained. The inner expansion element 32 may be a balloon that is inflated by injecting an inflation fluid through a connected lumen (not illustrated) or may be an expandable structure (like a stent-type structure, for example) covered by an impermeable membrane or by a substantially impermeable membrane. The membrane may be closed on both the proximal and distal ends or on either of the proximal and distal ends to substantially prevent blood flow through the stent to force the blood to flow only outside of the inner expansion element 32 to provide cooling to the electrodes 30.

FIGS. 3A and 3B are a side view and an end view, respectively, of the system 12 introduced in a blood vessel and illustrate how the spacer struts 26 keep the electrodes spaced apart from the vessel wall 34. These views also illustrate how the inner expansion element 32 serves to reduce the cross sectional area available for blood flow in the area of the electrodes 30. The electrodes 30 are preferably kept spaced from the outer surface of the inner expansion element 32 as well as from the vessel wall 34. In this embodiment, there are two spacer struts 26 for each electrode 30, one spacer strut disposed on either side of the electrode. One feature of this arrangement is that it keeps the area between the electrode and the vessel wall free from intervening material. Other suitable arrangements of spacer struts are within the purview of this invention.

FIG. 4 is a side view of another illustrative embodiment of the distal portion of a renal nerve ablation system 12. In this embodiment, the inner expansion member is omitted and the electrode struts are cantilevered, having a proximal end joined to the strut assembly and a free distal end (with the electrode thereupon). The distal end may terminate within the electrode or may extend distally beyond the electrode.

Features of the several illustrated embodiments may be readily combined with one another. For example, the cantilevered electrode struts of the FIG. 4 embodiment may be incorporated into the embodiment of FIG. 2, which has the inner expansion member 32.

FIG. 5 is a side view of another illustrative embodiment of the distal portion of a renal nerve ablation system 12. In this embodiment, the electrodes are spaced apart longitudinally, with a first set 44 of two electrodes and their corresponding spacer struts spaced distally from a second set 46. The inner expansion member 32 preferably extends under both sets. The inner expansion member 32 is shown as being formed as essentially one piece extending under both sets of electrodes. In other contemplated embodiment, the inner expansion member is formed from more than one lobe, such that there may be one lobe under the first set and a second lobe under the second set, with a narrower waist therebetween. In other contemplated embodiments, the system may include more than one expansion member. In other contemplated embodiments, each electrode 30 and that electrode's associated spacer struts 26 may be at a different longitudinal

location. There may also be more than four electrodes (or fewer) or more than two sets of electrodes, as desired.

FIGS. 6A, 6B, 6C and 6D illustrate electrodes 36 integral with electrode struts 38. "Integral with" in this context is intended to mean that the electrode and the electrode strut are both formed from the same precursor and can thus be said to be monolithic or of unitary construction. After the electrode and the strut are formed (by cutting a sheet or tube of material, for example), a strip of insulating material 40 may be applied around the perimeter of the electrode as illustrated in FIG. 6B or the central portion of the electrode may be plated with a layer 42 of platinum or other suitable conductive and non-oxidizing material as illustrated in FIG. 6C. Both the front surface and the back surface of the electrode may be plated with a layer 42. "Plating" refers not only to plating but to any suitable process for depositing a suitable material. Electro-plating, laser deposition, printing are all contemplated. FIG. 6D illustrates that in some instances it is desirable to have the insulating material 40 and the plating layer 42.

FIG. 7 illustrates a non-integral electrode 30 disposed on an electrode strut 28. The electrode may have a more rounded and three-dimensional ovoid shape when not formed from the same piece as the strut. Such an electrode may be made from a different material from the strut. For example, the strut may be made from nitinol and the electrode may be made from platinum.

FIGS. 8A and 8B are a side view and an end view, respectively, of a system 12' (which may be similar to other systems disclosed herein) introduced in a blood vessel 34 and illustrate how one or more trip struts 27 may be incorporated into such a system. Trip struts 27 are placed between the vessel wall 34 and the electrodes 30. In some cases, the trip strut 27 may be placed somewhat upstream from the electrode. FIG. 8A illustrates two trip struts 27 in a strut assembly 24, which allows the trip struts to be useful regardless of the direction of the blood flow. It is also contemplated that only one trip strut per electrode may be used. If, for example, the system is advanced into a renal artery as illustrated in FIG. 1, only the distal trip strut 27 may be used. The location of the trip strut allows it to increase the turbulence in blood flow past the vessel wall under the electrode to increase heat transfer. The trip strut 27 is illustrative of other contemplated boundary layer control elements that may be used. Other suitable boundary layer control elements include bumps, corners, expansions, surface roughness, trip wires, wings, fins, offset channels and the like. Such features may be attached to one or more of the struts of strut assemblies 24, to the electrodes 30, the inner expansion member 32 or to another suitable element of the system. For example, an expandable assembly incorporating such features may be attached to distal end region 22. Some embodiments also include an active infusion system that may infuse a fluid such as a saline solution into the area to be treated. Such a system may improve cooling and also increase turbulence for improved heat transfer. An active infusion system can be added to a system that includes the boundary control elements such as the trip struts 27.

Trip struts 27 are intended to increase heat transfer between a hot spot on the vessel wall caused by the ablation procedure and the fluid (usually blood) flow through the vessel by increasing the turbulence of the fluid flowing past the treatment location. Thus trip struts 27 are preferably placed somewhat upstream from the hot spot by placing them somewhat upstream of the electrode 30. Trip struts 27 are also preferable extend in a direction that is substantially perpendicular to the blood flow. This direction may be a

radial direction or may be (as shown in FIGS. 8A and 8B) a direction that is substantially perpendicular to a radius of the blood vessel. Struts 27 are also preferably not in contact with the blood vessel wall at the treatment location and thus are spaced away from the way and, in some instances, in an upstream direction from the treatment location.

The electrodes may be formed from any suitable material such as, but not limited to platinum, gold, stainless steel, cobalt alloys, or other non-oxidizing materials. In some instances, titanium, tantalum, or tungsten may be used. It is contemplated that the electrodes may take any shape desired, such as, but not limited to, square, rectangular, circular, oblong, etc. In some embodiments, the electrodes may have rounded edges in order to reduce the effects of sharp edges on current density. In some instances, the electrodes may have an aspect ratio of 2:1 (length to width).

FIG. 9 is an isometric view of the distal portions of an illustrative renal nerve modulation system 900 that apart from the components described with respect to FIG. 9 may be similar to other systems disclosed herein. System 900 comprises an expandable stent-like frame 902 that includes electrode pads 904. Pads 904 are disposed on the frame 902 in a staggered pattern. A system 900 may include any desired number of pads 904. Twelve pads 904 are shown in the figure but a lesser or greater number may be included. The pads are shown as circular but may be other shapes including, for example, ovals or oblongs. The frame 902 and the pads 904 are electrically conductive. Electrode pads 904 include a first side 906 that faces outwardly and contacts the wall of the blood vessel when expanded and a second side 908 that faces inward towards the center of the system 900. The frame 902 and the electrode pad 904, apart from the second side 908, are covered with an electrically insulative material. Only the second side 908 of the pad 904 has an exposed conductive surface. Thus when the system 900 is expanded in a blood vessel the active portion of the electrode that transmits the RF energy will not be in contact with the vessel wall. Power is provided through a conductor 905 attached to the proximal end of the frame 902 and travels through the frame 902 to the pads 904. This embodiment thus provides an alternative method of ablation using non-contact electrodes. In this embodiment, non-contact means that the active surface of the electrode is not in contact with the vessel wall. Preferably, frame 902 is self-expanding and thus is expanded when a catheter is proximally withdrawn relative to frame 902.

Embodiments of system 900 are contemplated using alternative construction techniques. For example, any conventional self-expanding stent configuration may be appropriate for use as frame 902. Pads 904 may be formed integral with the frame or formed separately and attached to the frame. If formed separately, the frame need not be the conductor. Separate conductors such as wires may provide power to the electrode pads. Pads 904 will have an insulative or non-conductive side which faces and makes contact with the vessel wall and an active side that faces away from the vessel wall.

It is contemplated that the systems described herein such as assembly 10/system 12 or system 900 (and/or other assemblies/systems disclosed herein) may be operated in a variety of modes. In one embodiment, the assembly 10 may be operated in a sequential unipolar ablation mode. The electrodes may each be connected to an independent power supply such that each electrode may be operated separately and current may be maintained to each electrode. In sequential unipolar ablation, one electrode may be activated such that the current travels from the electrode to a ground

electrode. After one electrode has been activated and then deactivated, another electrode may be activated such that current travels from that electrode to the ground electrode.

In another embodiment, the assembly **10** may be operated in a simultaneous unipolar ablation mode. In simultaneous unipolar ablation mode, the electrodes may be activated simultaneously such that current travels from each electrode to the ground electrode(s). In some instances, the electrodes may each be connected to an independent electrical supply such that current is maintained to each electrode. In this mode, more current may be dispersed radially. This may result in a more effective, deeper penetration compared to the sequential unipolar ablation mode.

In another embodiment, the assembly **10** may be operated in a bipolar mode. In this instance, two electrodes disposed at the treatment location may be 180° out of phase such that one electrode acts as the ground electrode (e.g. one cathode and one anode). As such current may flow around the elongate shaft from one electrode to the other electrode. In general, either sequential or simultaneous unipolar mode may penetrate more deeply than the bipolar mode. Any of the embodiments described herein may be operated in any of the above described modes.

In use, a system **12** may be introduced percutaneously as is conventional in the intravascular medical device arts. For example, a guide wire may be introduced percutaneously through a femoral artery and navigated to a renal artery using standard radiographic techniques. A guide catheter may be introduced over the guide wire and the guide wire is withdrawn. The system **12** may be introduced into the guide catheter with the strut assemblies **24** compressed within the sheath **14**. Alternatively, the sheath **14** may take the form of a guide catheter. Once the distal end of the system **12** is at the desired location within the renal artery, the sheath **14** may be withdrawn to allow the strut assemblies **24** to expand. If inner expansion element **32** is present, it may be expanded or allowed to expand to partially restrict the flow of blood through the treatment site. The electrodes **30** are activated to ablate nerve tissue. The sheath **14** may then be advanced over the system **12** to compress the strut assemblies **24** and then the sheath **14** and system **12** may be withdrawn out of the patient's body.

The system may be manufactured using the following technique. The strut assemblies **24** for a system **12** may be formed from a single tubular member. The tubular member may be cut to form the strut assemblies **25** including the spacer struts **26**, the electrode struts **28** and, in certain embodiments, the electrodes **30**. At this stage, however, the strut assemblies **24** are still joined to each other by tubular proximal and/or distal rings. The strut assemblies are then shaped and then the cut and shaped tubular member is slid over a shaft **21** and the proximal and/or distal ends of the strut assemblies are joined to the shaft **21**. At this point, the proximal and distal rings are cut off and removed to separate the strut assemblies from each other. Another layer may be slid over the proximal and/or distal ends of the strut assemblies to further secure the strut assembly to the shaft. For example, a heat shrink tube may be used as the additional layer at the proximal and distal ends of the strut assembly.

Those skilled in the art will recognize that the present invention may be manifested in a variety of forms other than the specific embodiments described and contemplated herein. Accordingly, departure in form and detail may be made without departing from the scope and spirit of the present invention as described in the appended claims.

What is claimed is:

1. A system for nerve modulation through a wall of a blood vessel, comprising:

an elongate member extending along a central elongate axis and having a proximal end and a distal end, the elongate member having a radially expandable member disposed proximate the distal end; and

a tubular sheath cooperatively engaged with the expandable member such that the expandable member is not expanded when in the tubular sheath and can expand when moved out of the tubular sheath,

the expandable member comprising a plurality of electrodes on an expandable frame wherein each of the plurality of electrodes has a first surface that is entirely electrically insulated and faces radially outwards relative to the expandable member and a second surface that is electrically conductive surface that and faces radially inwards towards a central longitudinal axis of the expandable member.

2. The system of claim **1**, wherein the expandable frame provides a conductive path to the plurality of electrodes and wherein the expandable frame is electrically insulated.

3. The system of claim **1**, wherein the expandable member is self-expanding.

4. The system of claim **1**, wherein at least some of the plurality of electrodes and the expandable frame are formed from the same material.

5. The system of claim **1**, wherein the plurality of electrodes are disposed on the expandable frame in an axially and circumferentially staggered pattern.

6. The system of claim **1**, wherein the expandable frame and the first surface of each of the plurality of electrodes is covered with an electrically insulative material.

7. The system of claim **1**, wherein the expandable frame extends to the proximal end of the elongate member.

8. The system of claim **1**, wherein the plurality of electrodes are each connected to an independent power supply.

9. A system for nerve modulation through a wall of a blood vessel, comprising:

an elongate member extending along a central elongate axis and having a proximal end and a distal end, the elongate member having a radially expandable member disposed proximate the distal end; and

a tubular sheath cooperatively engaged with the expandable member such that the expandable member is not expanded when in the tubular sheath and can expand when moved out of the tubular sheath,

the expandable member comprising a plurality of non-contact electrodes on an expandable frame, wherein each of the plurality of non-contact electrodes has a single electrically conductive surface, wherein the expandable member is configured such that when the expandable frame is expanded and in contact with a blood vessel wall, the electrically conductive surface of each of the plurality of non-contact electrodes does not contact the blood vessel wall and faces radially inward towards a central longitudinal axis of the expandable member.

10. The system of claim **9**, wherein the expandable frame is non-conductive, and conductor wires connect the plurality of non-contact electrodes to a conductor attached to the proximal end of the expandable frame.

11. The system of claim **9**, wherein the expandable member is self-expanding.

12. The system of claim **9**, wherein at least some of the plurality of non-contact electrodes and the expandable frame are formed from the same material.

11

13. The system of claim 9, wherein the plurality of non-contact electrodes are disposed on the expandable frame in an axially and circumferentially staggered pattern.

14. The system of claim 9, wherein the plurality of non-contact electrodes are each connected to an independent power supply. 5

15. A system for nerve modulation through a wall of a blood vessel, comprising:

an elongate member extending along a central elongate axis and having a proximal end and a distal end, the elongate member having a radially expandable member disposed proximate the distal end; and 10

a tubular sheath cooperatively engaged with the expandable member such that the expandable member is not expanded when in the tubular sheath and can expand when moved out of the tubular sheath, 15

the expandable member comprising an expandable frame having a plurality of widened regions axially and circumferentially staggered along the expandable frame, wherein each of the plurality of widened regions has a first completely electrically insulated surface that 20

12

faces radially outwards relative to the expandable member and a second electrically conductive surface that faces radially inwards towards a central longitudinal axis of the expandable member.

16. The system of claim 15, wherein the expandable frame is non-conductive, and conductor wires connect the plurality of widened regions to a conductor attached to the proximal end of the expandable frame.

17. The system of claim 15, wherein the expandable member is self-expanding.

18. The system of claim 15, wherein the plurality of widened regions are each connected to an independent power supply.

19. The system of claim 15, wherein the expandable frame extends to the proximal end of the elongate member.

20. The system of claim 15, wherein the expandable frame provides a conductive path to the plurality of widened regions and wherein the expandable frame is electrically insulated.

* * * * *